Research Guides
Each guide covers what the disease is, what treatment options exist, which questions to ask, and where to find the best care — organized by where you are in the journey.
Cancer 28 available, 14 coming
Sjögren’s Syndrome
Diagnosis, dry-eye and dry-mouth management, systemic treatment options, emerging therapies, clinical trials, and specialty centers.
Available NowHerpes (HSV-1 / HSV-2 / Zoster)
HSV-1 (oral), HSV-2 (genital), and herpes zoster (shingles/VZV) — diagnosis, antiviral and suppressive therapy, complications, pregnancy, and emerging treatments.
Available NowColon Cancer
Diagnosis, staging, surgery, adjuvant chemotherapy (IDEA framework), molecular testing (dMMR/MSI, RAS, BRAF V600E, HER2), Lynch syndrome, targeted therapies, ctDNA, clinical trials, and major centers.
Available NowGlioblastoma (GBM)
Standard treatment, clinical trials, repurposed therapies, regional medical centers, and what to do at every stage from diagnosis through recurrence.
Available NowLung Cancer (NSCLC)
Biomarker testing, targeted therapies (EGFR, ALK, KRAS G12C), immunotherapy, surgical advances, radiation, clinical trials, and comprehensive cancer centers.
Available NowMultiple Myeloma
Risk stratification, induction therapy, stem cell transplant, maintenance, CAR-T and bispecific antibodies, bone health, and smoldering myeloma monitoring.
Available NowNon-Hodgkin Lymphoma (NHL)
12+ NHL subtypes, standard treatments, CAR-T and bispecific antibodies, repurposed drugs, international approaches, diet and metabolic strategy, and high-volume centers.
Available NowPancreatic Cancer
Understanding PDAC and what resectable/borderline/advanced mean, warning signs & family risk, chemo options explained (incl. NALIRIFOX), the KRAS breakthrough & trials, choosing a high-volume center & Whipple recovery, enzymes & nutrition, pain & palliative care, and an honest word on hope.
Available NowProstate Cancer
Risk stratification, active surveillance, surgery, radiation, ADT & intensification, mCRPC, PSMA-targeted therapy, genomic testing, and clinical trials.
Available NowBreast Cancer
All four subtypes (HR+/HER2-, HER2+, HER2-low, triple-negative): diagnosis and staging, genomic testing (BRCA, Oncotype, PD-L1, ESR1, PIK3CA), surgery and radiation, endocrine and CDK4/6 therapy, HER2-targeted agents, ADCs, immunotherapy, metastatic care, trials, and major centers.
Available NowThyroid Cancer
Thyroid nodule evaluation, molecular testing (Afirma, ThyroSeq), Bethesda classification, surgery options, radioactive iodine therapy, TSH suppression, targeted therapies for RET/BRAF/NTRK mutations, active surveillance, medullary and anaplastic management, and clinical trials.
Available NowAcute Lymphoblastic Leukemia
~6K new/yr US. Blinatumomab moving into frontline consolidation (E1910); CAR-T (brexucabtagene, tisagenlecleucel); MRD-guided therapy.
Available NowAcute Myeloid Leukemia
~20K new/yr; ~11K deaths. Menin inhibitor revumenib (Revuforj, FDA 2024) for KMT2A/NPM1; expanding IDH1/2 and FLT3 inhibitors; oral azacitidine maintenance.
Available NowAdrenocortical Carcinoma
~1-2 per million/yr. Mitotane plus chemotherapy standard; immunotherapy and targeted trials; hormone-excess management.
Available NowAnal Cancer
~10K new/yr US. Immunotherapy in advanced disease; HPV-driven prevention and high-resolution-anoscopy screening (ANCHOR).
Available NowBladder Cancer
~83K new/yr US. Enfortumab vedotin + pembrolizumab (EV-302) transformed first-line metastatic; nadofaragene and N-803 for BCG-unresponsive NMIBC.
Available NowCastleman Disease
~5-6K new/yr US (all types). Siltuximab for idiopathic multicentric disease; sirolimus and JAK-pathway trials; CDCN-driven research.
Available NowCervical Cancer
~14K new/yr US. Pembrolizumab + chemoradiation (KEYNOTE-A18); tisotumab vedotin for recurrent disease; HPV-driven prevention.
Available NowCholangiocarcinoma (Bile Duct Cancer)
~8-12K new/yr US. FGFR2 inhibitors (pemigatinib, futibatinib), IDH1 inhibitor ivosidenib, durvalumab+chemo (TOPAZ-1) first-line.
Available NowChronic Lymphocytic Leukemia
~21K new/yr; ~200K prevalence. Fixed-duration BTK+BCL2 (venetoclax-based) combinations; pirtobrutinib for BTK-resistant disease.
Cutaneous T-Cell Lymphoma (Mycosis Fungoides)
~3K new/yr US. Mogamulizumab; expanding skin-directed and systemic options; stage-driven therapy.
Desmoid Tumors
~5-6 per million/yr. Nirogacestat (Ogsiveo, 2023) — first FDA-approved therapy; gamma-secretase inhibition.
Available NowDiffuse Large B-Cell Lymphoma
~25K new/yr US. Bispecifics epcoritamab and glofitamab; pola-R-CHP first-line (POLARIX); CAR-T moved to second line.
Diffuse Midline Glioma / DIPG (Pediatric)
~300-400 new/yr US. Dordaviprone (Modeyso) accelerated approval (2025) for H3 K27M-mutant disease — first targeted option.
Esophageal Cancer
Adeno vs squamous, Barrett’s & early warning signs, surgery and recovery, chemo/radiation, immunotherapy explained, fertility & sexual health, caregiving, trials, and a hopeful, plain-language path through every stage.
Ewing Sarcoma
~200 new/yr US. Refined multimodal therapy; trials of targeted agents; survivorship-focused care.
Gastric Cancer
~27K new/yr US. Zolbetuximab (Vyloy) for Claudin 18.2-positive tumors; trastuzumab deruxtecan; IO by PD-L1 status.
Available NowHead and Neck Cancer
~71K new/yr US. Cancer by subsite (mouth, throat, voice box, nasopharynx), HPV-related throat cancer, surgery (incl. TORS), radiation and chemoradiation, perioperative pembrolizumab (KEYNOTE-689), immunotherapy for advanced disease, organ preservation, and protecting voice and swallowing.
Available NowHepatocellular Carcinoma (Liver Cancer)
~42K new/yr US. Atezolizumab+bevacizumab and durvalumab+tremelimumab first-line; IMbrave050 adjuvant data; expanding earlier-stage IO.
Low-Grade / IDH-Mutant Glioma
~5-6K new/yr US. Vorasidenib (Voranigo, FDA 2024) — first targeted therapy for grade 2 IDH-mutant glioma (INDIGO trial).
Melanoma
~100K new/yr US. Tumor-infiltrating lymphocyte therapy lifileucel (Amtagvi, 2024); adjuvant IO; mRNA-4157 personalized vaccine (with pembrolizumab) phase 3.
Merkel Cell Carcinoma
~3K new/yr US. Avelumab and pembrolizumab — checkpoint inhibitors transformed this aggressive skin cancer; neoadjuvant IO trials.
Mesothelioma
~3K new/yr US. Nivolumab+ipilimumab first-line (CheckMate-743); perioperative IO trials; ADCs in development.
Neuroblastoma
~700-800 new/yr US. Anti-GD2 immunotherapy (dinutuximab, naxitamab) standard in high-risk disease; eflornithine maintenance.
Osteosarcoma
~1K new/yr US. Limb-salvage surgery advances; immunotherapy and targeted trials; metastatic-disease research.
Ovarian Cancer
~20K new/yr; ~12K deaths. PARP-inhibitor maintenance (HRD-guided); mirvetuximab soravtansine for folate-receptor-alpha-positive disease.
Available NowRenal Cell Carcinoma (Kidney Cancer)
~82K new/yr US. IO-TKI combinations standard; belzutifan (HIF-2alpha inhibitor) for VHL and advanced disease; adjuvant pembrolizumab.
Retinoblastoma
~200-300 new/yr US. Intra-arterial and intravitreal chemotherapy enable eye preservation; genetic (RB1) testing and counseling.
Small Cell Lung Cancer
Chemo-immunotherapy for both stages, consolidation durvalumab (ADRIATIC), brain-protecting radiation, lurbinectedin maintenance, and the DLL3-targeted bispecific tarlatamab (Imdelltra, full FDA approval Nov 2025) for relapse — with paraneoplastic-syndrome care, side-effect management, and survivorship.
Soft Tissue Sarcoma
~13K new/yr US. Subtype-specific advances; nirogacestat for desmoids; afamitresgene autoleucel (T-cell therapy) for synovial sarcoma (2024).
Thymoma & Thymic Carcinoma
~400-500 new/yr US. Refined multimodal therapy; immunotherapy use tempered by autoimmune risk; paraneoplastic awareness.
Uveal Melanoma
~2.5K new/yr US. Tebentafusp (Kimmtrak) — first therapy to extend overall survival in metastatic disease (HLA-A*02:01 patients).
Neurological 15 available, 26 coming
Aging, Compression & the Nervous System
Degenerative spine disease, pinched nerves (radiculopathy), spinal-cord compression (cervical myelopathy), and lumbar spinal stenosis — how to tell them apart, the emergency warning signs (cauda equina), non-surgical care vs. when decompression surgery helps, why timing matters for cord compression, the treatable-compression-vs-ALS question, and pregnancy considerations.
Available NowAlzheimer's Disease
Understanding AD stages, amyloid-targeting therapies (lecanemab, donanemab), cognitive support, caregiver guidance, clinical trials, and specialty memory centers.
Available NowALS (Amyotrophic Lateral Sclerosis)
Gold Coast criteria, genetic testing (SOD1/C9orf72), disease-modifying medicines, multidisciplinary ALS clinic care, breathing support, communication tools, caregiver guidance, and advance care planning.
Available NowMSA & Alpha-Synucleinopathy Addendum
Addendum covering MSA, Dementia with Lewy Bodies (DLB), and Pure Autonomic Failure (PAF). Differential diagnosis, MDS 2022 MSA criteria, autonomic management, and supplement evidence grades.
Available NowMyasthenia Gravis
FcRn blockers, complement inhibitors, thymectomy, crisis management, medication interactions, pregnancy considerations, and specialist referral.
Available NowParkinson’s Disease
Stage-based guide covering medications, exercise programs, DBS, emerging therapies, clinical trials, and specialty centers with a dedicated Canada tab.
Angelman Syndrome
~1 in 12-20K. Antisense-oligonucleotide programs targeting UBE3A in trials; symptomatic-care optimization.
CADASIL
~1 in 25-50K. Genetic diagnosis (NOTCH3); supportive management; emerging therapeutic research.
Cerebral Cavernous Malformation
~1 in 200-600. Propranolol and other repurposed-drug trials; familial-form genetic testing; imaging-surveillance guidance.
Charcot-Marie-Tooth Disease
The most common inherited neuropathy (~1 in 2,500). Subtypes and genetics, diagnosis, the drugs to avoid (vincristine contraindicated), telling CMT from treatable look-alikes (CIDP, hereditary ATTR amyloidosis), braces and supportive care that keep you mobile, foot care, pain, CMT in children, the CMT1A treatment trials (PXT3003), and family planning.
Chronic Inflammatory Demyelinating Polyneuropathy
~20-30K US. Efgartigimod (Vyvgart) approved for CIDP (2024); maintenance immunoglobulin optimization.
Chronic Migraine
~4M US with chronic migraine. CGRP monoclonal antibodies and oral gepants for prevention and acute use; growing real-world evidence.
Cluster Headache
~1 in 1K. Galcanezumab for episodic cluster; non-invasive vagus nerve stimulation; oxygen and acute-treatment optimization.
Dravet Syndrome
~1 in 15-16K births. Fenfluramine and cannabidiol approved; STK-001 antisense oligonucleotide and gene-therapy trials.
Drug-Resistant Epilepsy
~1M US with refractory seizures. New antiseizure medications (cenobamate); responsive neurostimulation and laser ablation; surgical-evaluation push.
Dystonia
The treatable look-alikes you must not miss (dopa-responsive dystonia, Wilson disease), the types, botulinum toxin (incl. longer-acting daxibotulinumtoxinA), deep brain stimulation, pain and emotional-health care, sensory tricks, dystonic-storm warning signs, and support.
Essential Tremor
~7M US. MRI-guided focused ultrasound thalamotomy — incisionless option; expanding bilateral treatment.
Fragile X Syndrome
~1 in 4-7K. Targeted trials (e.g., zatolmilast/BPN14770 PDE4D inhibitor) for cognition; refined behavioral care.
Friedreich Ataxia
~5K US. Omaveloxolone (Skyclarys, 2023) — first-ever approved treatment; gene therapy and frataxin-replacement programs advancing.
Available NowFrontotemporal Dementia
~50-60K US. Progranulin-raising therapies (latozinemab) and C9orf72-targeted ASOs in trials; AC Immune and others advancing.
Guillain-Barre Syndrome
~1-2 per 100K/yr. IVIG and plasma exchange standard; complement inhibitor (eculizumab) and other trials for severe disease.
Hereditary ATTR Amyloidosis with Polyneuropathy
~10-40K US (underdiagnosed). TTR silencers patisiran, vutrisiran, eplontersen; NTLA-2001 (Nextriva) one-time CRISPR therapy advancing.
Hereditary Spastic Paraplegia
~1-5 per 100K. Gene-discovery expansion; subtype-specific trials emerging; supportive-care optimization.
Huntington's Disease
~41K symptomatic US; ~200K at-risk. AMT-130 AAV gene therapy showed first-ever signal of slowed progression (2025); huntingtin-lowering ASO programs continuing.
Lambert-Eaton Myasthenic Syndrome
~3 per million. Amifampridine (Firdapse/Ruzurgi); strong association with small-cell lung cancer driving cancer screening.
Leber Hereditary Optic Neuropathy
~100 new/yr US. Idebenone; lenadogene nolparvovec gene-therapy trials; mitochondrial-targeted approaches.
Lennox-Gastaut Syndrome
~30-50K US. Cannabidiol and fenfluramine approved; cenobamate and other agents studied; dietary and device options.
Lewy Body Dementia
~1.4M US. Refined biomarkers (skin/CSF alpha-synuclein seed amplification); neuroleptic-sensitivity awareness; symptomatic-care advances.
Available NowVascular Dementia
The 2nd most common — and most preventable — dementia. The types and how it differs from Alzheimer's, diagnosis, why controlling blood pressure and preventing strokes is the real treatment (SPRINT-MIND), mixed dementia, daily strategies, and resources. “What's good for the heart is good for the brain.”
Available NowMixed Dementia
The most common substrate of dementia in older adults (Alzheimer’s + cerebrovascular). Treat both processes; anti-amyloid eligibility tempered by vascular/microbleed burden.
Available NowNormal Pressure Hydrocephalus
One of the few potentially reversible causes of dementia. The Hakim triad (gait, thinking, bladder), diagnosis by imaging and the tap test, shunt surgery and what the 2025 PENS trial showed (gait benefit), realistic expectations, falls, and finding an experienced center.
Available NowParkinson's Disease Dementia
Dementia >1 year after Parkinson’s motor onset (the 1-year rule vs DLB). Rivastigmine FDA-approved; the critical neuroleptic-sensitivity warning; treating reversible decline (delirium); fluctuations, hallucinations, non-motor care, caregiver support, and the (thin) trial pipeline.
Available NowWernicke-Korsakoff Syndrome
A preventable, treatable thiamine-deficiency disorder. The Wernicke emergency (urgent injected thiamine before glucose — treat on suspicion), the chronic Korsakoff amnesia and its outlook, causes (alcohol, bariatric surgery, hyperemesis), prevention, and support — with the warning signs that should prompt urgent care.
Available NowHIV-Associated Dementia (HAND)
The ANI/MND/HAD spectrum. Severe dementia is now rare with effective HIV treatment — sustained viral suppression protects the brain. Covers the many treatable causes of thinking problems, CSF viral escape, aging and the brain, daily strategies, and support.
Available NowCreutzfeldt-Jakob Disease (Prion)
Rapidly progressive prion dementia with myoclonus and ataxia; RT-QuIC + DWI-MRI diagnosis. No disease-modifying treatment — supportive/palliative; median survival months.
MOG Antibody Disease
~1-2 per 100K. Newly defined entity (MOGAD); rozanolixizumab and other trials; distinguished from MS and NMOSD.
Moyamoya Disease
~1 in 100K US (higher in East Asia). Revascularization surgery (bypass) is mainstay; refined patient selection and imaging.
Myotonic Dystrophy
The multisystem muscle disease where the heart and anesthesia — not the visible weakness — carry the biggest risk. DM1 vs DM2, why monitoring matters when you feel well, treating myotonia, the congenital form, cardiac & breathing surveillance, pregnancy and inheritance, and the RNA-targeted trials.
Available NowNarcolepsy
~150-200K US. Orexin-receptor agonists (oveporexton/TAK-861) in phase 3 — potentially disease-targeted, not just symptomatic.
Neuroendocrine Tumors (NETs)
~12K new/yr US; rising prevalence. Lutetium-177 dotatate (Lutathera) expanding to earlier lines; somatostatin-analog and targeted-agent advances.
Neurofibromatosis Type 1
A lifespan guide: the features & diagnosis, age-based surveillance, the cancer (MPNST) warning signs, children's eye monitoring (optic pathway glioma), learning & school support, treatable high blood pressure, MEK-inhibitor medicines (selumetinib, mirdametinib), trials, and family planning.
Available NowNeuromyelitis Optica Spectrum Disorder
~15K US. Four approved biologics: eculizumab, satralizumab, inebilizumab, and ravulizumab (2024) — relapse prevention transformed.
Available NowRestless Legs Syndrome
~7-10M US with significant symptoms. Shift away from dopamine agonists (augmentation risk) toward alpha-2-delta ligands and iron repletion.
Rett Syndrome
~6-9K US. Trofinetide (Daybue, 2023) — first-ever approved drug; gene-therapy programs (e.g., TSHA-102) in trials.
Spinocerebellar Ataxias
~1-5 per 100K. Troriluzole and gene-specific antisense programs in trials; expanded genetic testing.
Trigeminal Neuralgia
~150K US. Microvascular decompression and modern radiosurgery/ablation; newer sodium-channel-blocker research.
Tuberous Sclerosis Complex
~50K US. mTOR inhibitors (everolimus) for SEGAs/angiomyolipomas; cannabidiol for seizures; surveillance protocols.
Autoimmune 3 available, 14 coming
Multiple Sclerosis
Progressive-MS emphasis: diagnosis, disease-modifying therapies, BTK inhibitors, symptom management, clinical trials, and resources for patients and caregivers.
Available NowANCA-Associated Vasculitis (GPA/MPA)
~40-50K US. Avacopan (Tavneos) — oral C5a-receptor blocker enabling major steroid reduction; rituximab maintenance optimization.
Adult-Onset Still's Disease
~1-2 per million/yr. IL-1 (anakinra, canakinumab) and IL-6 inhibitors; recognition of macrophage-activation-syndrome risk.
Autoimmune Hepatitis
~100-200K US. Standard steroid/azathioprine plus emerging steroid-sparing strategies; refined diagnostic scoring.
Axial Spondyloarthritis
~1.5-3M US (incl. non-radiographic). IL-17 inhibitors and JAK inhibitors; non-radiographic axSpA recognition; earlier diagnosis push.
Behcet's Disease
~1 in 20K US (higher along Silk Road). Apremilast for oral ulcers; TNF and IL-1 inhibitors; organ-specific treatment frameworks.
Bullous Pemphigoid
~2-5 per 100K/yr (elderly). Dupilumab approved for bullous pemphigoid (2025) — first targeted biologic; steroid-sparing.
Dermatomyositis & Polymyositis
~10 per 100K. IVIG (Octagam 10%) approved for dermatomyositis; myositis-specific antibody-driven subtyping; JAK inhibitors.
Familial Mediterranean Fever
~1 in 200-1K in at-risk populations. Colchicine remains first-line; IL-1 inhibitors for colchicine-resistant disease; MEFV genetic testing.
Giant Cell Arteritis
~228K US over 50. Tocilizumab steroid-sparing; new IL-6 and GM-CSF-pathway trials; fast-track diagnostic pathways.
IgG4-Related Disease
~1-5 per 100K (likely underdiagnosed). Inebilizumab (MITIGATE trial, 2025) — first agent with a dedicated IgG4-RD program; rituximab widely used.
Inclusion Body Myositis
~5-10 per 100K over 50. No approved treatment; ulnar/finger-flexor pattern recognition; trials of myostatin and autophagy-targeted agents.
Pemphigus Vulgaris
~1-5 per million/yr. Rituximab first-line (with steroids) is now standard; FcRn and other targeted agents in trials.
Psoriatic Arthritis
~1.5M US. IL-17, IL-23, and JAK inhibitors; bimekizumab; domain-based treatment selection.
Rheumatoid Arthritis
~1.3M US. Diagnosis and blood tests, treat-to-target care, methotrexate and DMARDs, biologics and JAK inhibitors (with safety), pregnancy planning, and protecting your joints.
Available NowSjogren's Syndrome
~0.4-3.1M US (wide estimates). Ianalumab, dazodalibep, and other B-cell/co-stimulation agents in phase 3 — first potential disease-modifying drugs.
Stiff Person Syndrome
~1-2 per million. No approved disease-specific drug; rituximab and immunotherapy used off-label; GAD/glycine-receptor antibody subtyping.
Systemic Sclerosis (Scleroderma)
~100K US. Tocilizumab and nintedanib for SSc-ILD; autologous stem-cell transplant; CD19 CAR-T trials showing remission.
Heart & Vascular 5 available, 12 coming
Atrial Fibrillation
Rate vs. rhythm control, ablation, anticoagulation strategies, stroke prevention, lifestyle modifications, and shared decision-making.
Available NowATTR Cardiomyopathy
TTR stabilizers (tafamidis, acoramidis), gene silencers, cardiac monitoring, genetic testing, transplant pathways, and multidisciplinary care.
Available NowHeart Failure
Diagnosis, GDMT optimization, HFpEF treatment (SGLT2i, tirzepatide), ATTR-CM (tafamidis, acoramidis), devices, transplant, clinical trials, and patient resources.
Available NowPulmonary Arterial Hypertension
Sotatercept, combination therapy, risk stratification, right heart catheterization, exercise, transplant evaluation, and PH center referral.
Available NowStroke Prevention & Recovery
Stroke biology, prevention (Life’s Essential 8), three recovery phases, rehabilitation settings, neuromodulation, spasticity management, international approaches, and comprehensive stroke centers.
Aortic Stenosis
~1.5M+ US (moderate-severe). EARLY TAVR (2024) supports earlier intervention in asymptomatic severe disease; TAVR durability data maturing.
Arrhythmogenic Cardiomyopathy
~1 in 2-5K. Genetic-testing-driven diagnosis; exercise-restriction evidence; risk-stratified ICD decisions.
Brugada Syndrome
~1 in 2K (higher in Asia). Risk-stratification refinements; ajmaline-challenge use; ICD and ablation decision frameworks.
Cardiac Sarcoidosis
Underdiagnosed subset of sarcoidosis. Advanced imaging (cardiac MRI/FDG-PET) recognition; immunosuppression plus device therapy protocols.
Coronary Artery Disease (residual risk)
~20M US. Aggressive LDL lowering (statins, ezetimibe, PCSK9 inhibitors incl. once-monthly lerodalcibep, inclisiran, bempedoic acid), lipoprotein(a), colchicine for residual inflammation, blood thinners, stents vs. bypass, cardiometabolic medicines, and cardiac rehab.
Hereditary Hemorrhagic Telangiectasia
~1 in 5K (largely undiagnosed). Pomalidomide (PATH-HHT trial, 2024) reduced bleeding; anti-VEGF strategies; systemic therapy emerging.
Long QT Syndrome
~1 in 2K. Genotype-specific management; beta-blocker selection by subtype; left cardiac sympathetic denervation; gene-specific trials.
Marfan Syndrome
~1 in 5K. Losartan plus beta-blocker; refined aortic-surveillance and surgical-threshold guidance.
Mitral Regurgitation
~4M US. Transcatheter edge-to-edge repair expanding; new replacement devices; functional-vs-degenerative pathways.
Peripheral Artery Disease
~10-12M US. Low-dose rivaroxaban plus aspirin (VOYAGER PAD); revascularization and supervised-exercise advances.
Tricuspid Regurgitation
~1.6M US with significant TR. Transcatheter tricuspid repair (TriClip, FDA 2024) and replacement systems — first device options.
Venous Thromboembolism (DVT/PE)
~900K events/yr US. Catheter-directed and mechanical thrombectomy for selected PE/DVT; refined DOAC duration strategies.
Digestive & Liver 5 available, 10 coming
Liver Disease
MASLD/MASH (fatty liver disease), fibrosis staging, approved medications (resmetirom, semaglutide), cirrhosis management, liver cancer screening, transplant pathway, and lifestyle interventions.
Available NowPBC (Primary Biliary Cholangitis)
Ursodiol, obeticholic acid, elafibranor, fibrate therapy, pruritus management, bone health, transplant evaluation, and monitoring.
Available NowUlcers
All ulcer types: peptic ulcers, diabetic foot ulcers, venous leg ulcers, pressure injuries. Diagnosis, treatment, prevention, and patient resources.
Achalasia
~1 in 100K/yr. Per-oral endoscopic myotomy (POEM) widely adopted; high-resolution-manometry subtyping guides therapy.
Acute Hepatic Porphyria
~1 in 100K (symptomatic rarer). Givosiran (Givlaari) RNAi prophylaxis dramatically reduces attacks; refined diagnostic testing.
Celiac Disease
~2M US (most undiagnosed). First non-dietary therapies in trials (e.g., gluten-degrading enzymes, immune-tolerance approaches).
Chronic Pancreatitis
~90-150K US. Total pancreatectomy with islet autotransplantation for selected patients; endoscopic and pain-management advances.
Eosinophilic Esophagitis
~150K+ US, rising fast. Dupilumab (Dupixent) — first FDA-approved drug for EoE; budesonide oral suspension (Eohilia).
Gastrointestinal Stromal Tumor
~5-6K new/yr US. Ripretinib and avapritinib for specific mutations; mutation-guided sequencing of tyrosine kinase inhibitors.
Gastroparesis
~5M US with symptoms. Limited drug options; gastric per-oral endoscopic myotomy (G-POEM); newer prokinetic and device research.
Hepatitis B
~1.9-2.4M US. Understanding your blood markers, antiviral suppression (tenofovir, entecavir), liver-cancer surveillance, perinatal prevention & vaccination, hepatitis D (now treatable with bulevirtide), and the functional-cure pipeline (bepirovirsen).
Available NowHepatitis C
~2.4M US. Curable for almost everyone with an 8-12 week course of well-tolerated pills (Mavyret, Epclusa). Universal screening, the 2025 same-visit point-of-care test-and-treat model, cirrhosis care, special populations, drug interactions, and preventing reinfection after cure.
Primary Sclerosing Cholangitis
~30-50K US. No approved disease-modifying drug yet; norUDCA, FXR/PPAR agents, and antibiotic-strategy trials active.
Short Bowel Syndrome
~10-20K US on parenteral support. Teduglutide (GLP-2 analog) reduces parenteral-nutrition dependence; next-generation GLP-2 agents (apraglutide).
Wilson Disease
~9-10K US. New chelation options and trientine formulations; bis-choline tetrathiomolybdate trials; gene therapy programs.
Blood & Immune 6 available, 8 coming
Sickle Cell Disease
Hydroxyurea, voxelotor, crizanlizumab, L-glutamine, gene therapy (Casgevy, Lyfgenia), pain crisis management, and transition to adult care.
Aplastic Anemia
~2-3 per million/yr. Eltrombopag added to immunosuppression as frontline (improves response); transplant-vs-IST decisions refined.
Diamond-Blackfan Anemia
~25-35 new/yr US. Steroids and transfusion standard; gene-therapy and novel-agent trials; ribosomal-genetics insight.
Fanconi Anemia
~1 in 130K births. Hematopoietic transplant refinements; gene therapy trials; intensive cancer-surveillance protocols.
Hemophagocytic Lymphohistiocytosis
~1 in 100K children; adult forms underdiagnosed. Emapalumab (anti-IFN-gamma) approved; refined HLH-2004 and trigger-directed treatment.
Hemophilia A & B
Severity classification, factor replacement therapy, non-factor prophylaxis (emicizumab, fitusiran, concizumab, marstacimab), gene therapy (Hemgenix, Roctavian), Altuviiio, inhibitor management, and musculoskeletal care.
Available NowHereditary Angioedema
~1 in 50K US. Donidalorsen and garadacimab approved 2025; oral prophylaxis (berotralstat); NTLA-2002 one-time CRISPR therapy in trials.
Available NowImmune Thrombocytopenia
~60-125K US. How low platelets are diagnosed, when to treat vs monitor, steroids and IVIG, platelet-boosting TPO agonists, fostamatinib, rituximab and splenectomy, newer agents (rilzabrutinib, FDA-approved 2025), managing bleeding, and pregnancy.
Inborn Errors of Immunity (SCID/CGD)
SCID ~1 in 58K births; many IEI types. Gene therapies for SCID and other IEIs; newborn SCID screening now universal in the US.
Myelodysplastic Syndromes
~15-20K new/yr US. Luspatercept first-line for lower-risk anemia (COMMANDS); imetelstat (Rytelo, 2024); molecular IPSS-M risk model.
Available NowMyelofibrosis
~13-20K US. Momelotinib (2023) for anemic patients; pacritinib; pelabresib and navitoclax combination trials.
Paroxysmal Nocturnal Hemoglobinuria
~1 in 100K US. Factor B/D inhibitors iptacopan (Fabhalta) and danicopan; pegcetacoplan — oral and proximal-complement options.
Polycythemia Vera
~100K US. Ropeginterferon alfa-2b (Besremi) — first interferon approved for PV; rusfertide (hepcidin mimetic) phase 3.
Thrombotic Thrombocytopenic Purpura
~3-4 per million/yr. Caplacizumab added to plasma exchange and immunosuppression; rituximab; recombinant ADAMTS13 for congenital TTP.
Metabolic & Genetic 6 available, 8 coming
Diabetes
Type 2 remission science, GLP-1 and dual agonist medicines, metabolic surgery, Type 1 technology (CGM, automated insulin delivery), complications, supplements, and action tools.
Elevated Lipoprotein(a)
~64M US with high Lp(a). Pelacarsen, olpasiran, and lepodisiran — Lp(a)-lowering agents in phase 3; first potential targeted therapy.
Erythropoietic Protoporphyria
~1 in 75-200K. Afamelanotide (Scenesse) increases pain-free light exposure; dersimelagon (oral) trials.
Fabry Disease
~3-5K diagnosed US (underdiagnosed). Pegunigalsidase alfa (Elfabrio); oral chaperone migalastat; gene therapy and substrate-reduction trials.
Available Now Ultra-Rare — First Guide WorldwidePUS7 Deficiency (IDDABS)
~15 patients worldwide. Pseudouridine synthase 7 deficiency causing ID, microcephaly, self-injury. AAV9 gene therapy potential. 4-LLM consensus verified.
Familial Hypercholesterolemia
~1 in 250 (~1.3M US, mostly undiagnosed). Inclisiran (twice-yearly siRNA), evinacumab for homozygous FH, lerodalcibep; cascade screening.
Gaucher Disease
~6K US. Established enzyme replacement and substrate reduction; gene therapy (PR001/LY3884961) trials; GBA1-Parkinson link research.
Lysosomal Acid Lipase Deficiency
~1 in 40-300K. Sebelipase alfa (Kanuma) enzyme replacement — disease-altering for Wolman disease and CESD.
Mitochondrial Diseases (MELAS/Leigh)
~1 in 5K combined. Supportive 'mito cocktails'; gene-specific and substrate trials; refined diagnostic genomics.
Niemann-Pick Disease Type C
~1 in 100-150K. Levacetylleucine (Aqneursa, 2024) and arimoclomol approved — first disease-targeted options.
Phenylketonuria
~16-20K US. Sepiapterin (Sephience, 2025) — new oral option; pegvaliase (Palynziq) for adults; gene-editing programs.
Available NowPompe Disease
~3-5K US. Avalglucosidase alfa (Nexviazyme) and cipaglucosidase alfa + miglustat (Pombiliti) — improved enzyme therapies.
Prader-Willi Syndrome
~1 in 15-30K. Diazoxide choline (DCCR) and other trials for hyperphagia; growth-hormone and behavioral management.
Urea Cycle Disorders
~1 in 35K births. Nitrogen-scavenger therapies; liver transplant; mRNA and gene-therapy programs in development.
Musculoskeletal 2 available, 9 coming
Scoliosis
Curve monitoring, bracing, surgical options (fusion, VBT), physical therapy, pain management, adult degenerative scoliosis, and specialist referral.
Available NowAchondroplasia
~10K US. Vosoritide (Voxzogo) — first drug to address growth; oral infigratinib (FGFR inhibitor) trials.
Facioscapulohumeral Muscular Dystrophy
~16-40K US. Losmapimod (DUX4-pathway) phase 3 trials; improved genetic diagnostics.
Fibromyalgia
~4M US adults. Refined multimodal management; central-sensitization framework; emerging neuromodulation research.
Gout (refractory/tophaceous)
~9M US (subset refractory). Pegloticase co-administered with methotrexate (improves response/durability); treat-to-target urate lowering.
Limb-Girdle Muscular Dystrophy
~2 per 100K. Multiple gene-therapy programs by subtype; precise genetic subtyping increasingly essential.
Mucopolysaccharidoses (MPS I/II/III)
~1 in 25K combined births. Enzyme replacement; intrathecal and gene-therapy programs (e.g., for Sanfilippo) advancing.
Osteoarthritis
~33M US. No disease-modifying drug yet; trials of NGF inhibitors and structure-modifying agents; weight-loss/GLP-1 impact.
Osteoporosis
~10M US. Bone-density (DXA) & FRAX fracture risk, calcium/vitamin D & exercise, bisphosphonates and denosumab, bone-building medicines (teriparatide, abaloparatide, romosozumab), anabolic-first sequencing, drug holidays, and the never-stop-denosumab-alone rule.
Polymyalgia Rheumatica
~700K US. Sarilumab approved for PMR (2023) — first biologic option; steroid-tapering strategies.
Vascular Ehlers-Danlos Syndrome
~1 in 50-200K. Celiprolol shown to reduce arterial events; genetic confirmation; emergency-planning protocols.
Respiratory 6 available, 5 coming
COPD
Inhaler therapy optimization, pulmonary rehabilitation, exacerbation prevention, oxygen therapy, lung volume reduction, and end-of-life planning.
Available NowCystic Fibrosis
CFTR modulators (Trikafta, Alyftrek), pulmonary management, nutrition, fertility, transplant, and the transition from pediatric to adult care.
Available NowIPF & Pulmonary Fibrosis
What pulmonary fibrosis is and the realistic outlook, getting an accurate diagnosis at an ILD center, antifibrotics explained (nintedanib, pirfenidone, nerandomilast/Jascayd) with side-effect tips, staying active, oxygen, transplant, exacerbation warning signs, family planning & inherited risk, trials, and a hopeful path through every stage.
Available NowAlpha-1 Antitrypsin Deficiency
~100K symptomatic; vastly underdiagnosed. Augmentation therapy plus emerging RNAi (fazirsiran) for liver disease; gene therapy programs.
Available NowBronchiectasis (non-CF)
~350-500K US. Brensocatib (DPP-1 inhibitor) — ASPEN trial positive, FDA approval 2025; first disease-modifying drug for bronchiectasis.
Chronic Rhinosinusitis with Nasal Polyps
~4M+ US. Biologics dupilumab, omalizumab, and mepolizumab — first drug class to shrink polyps and cut surgery.
Connective Tissue Disease-Associated ILD
Hundreds of thousands US (across CTDs). Nintedanib for progressive fibrosing ILD; nerandomilast (FIBRONEER-ILD) expanding antifibrotic options.
Long COVID
Millions US (estimates vary widely). No approved treatment; RECOVER trials and mechanistic studies (immune, autonomic, microclot, viral persistence) maturing.
Lymphangioleiomyomatosis
~3-5 per million women. Sirolimus stabilizes lung function; everolimus and newer mTOR-pathway trials; VEGF-D biomarker.
Sarcoidosis
~150-200K US. How this multisystem granulomatous disease is diagnosed, when to treat vs monitor, steroids and steroid-sparing medicines (methotrexate), infliximab, heart/nerve/eye/skin involvement, managing fatigue, advanced lung disease, and an honest read of the emerging-therapy pipeline.
Available NowSevere Asthma
~2.5M+ US with severe disease. Tezepelumab (anti-TSLP) covers eosinophil-low patients; expanding biologic landscape; biologic-driven remission as a goal.
Skin 1 available, 8 coming
Alopecia Areata
~700K US with active disease. Oral JAK inhibitors baricitinib, ritlecitinib, and deuruxolitinib (2024) — first systemic approvals.
Atopic Dermatitis (Eczema)
~16.5M US adults. Daily skin-barrier care, topical steroids and steroid-free creams, phototherapy, biologic injections (dupilumab plus newer IL-13 and IL-31 options), oral JAK-inhibitor pills, managing itch, sleep and infections, and eczema in children.
Chronic Spontaneous Urticaria
~1.5M US at any time. Omalizumab established; dupilumab approved (2025); remibrutinib (BTK inhibitor) trials.
Epidermolysis Bullosa
~25-30K US. Beremagene geperpavec (Vyjuvek) — first topical gene therapy (2023); birch-bark gel (Filsuvez); prademagene cell therapy.
Generalized Pustular Psoriasis
~1-7 per million. Spesolimab (Spevigo) — first approved IL-36-receptor antibody for flares and prevention.
Hidradenitis Suppurativa
~1% of US population. Secukinumab and bimekizumab approved; IL-17 and other biologics expanding beyond adalimumab.
Prurigo Nodularis
~150-200K US. Dupilumab and nemolizumab approved — first FDA-approved therapies for this intensely itchy disease.
Psoriasis (moderate-severe)
~7.5M US. Bimekizumab (dual IL-17A/F) and deucravacitinib (oral TYK2) — high skin-clearance options.
Vitiligo
~2-3M US. Ruxolitinib cream (Opzelura) — first FDA-approved repigmentation therapy; oral JAK inhibitors in trials.
Kidney 2 available, 3 coming
IgA Nephropathy
New targeted therapies (sparsentan, iptacopan, budesonide), proteinuria management, dietary considerations, kidney function preservation, and transplant planning.
Available NowChronic Kidney Disease
~35M US. SGLT2 inhibitors and finerenone slow progression; FLOW trial — semaglutide reduces kidney events; GLP-1 era.
Focal Segmental Glomerulosclerosis
~5-7 per million/yr US. Sparsentan (Filspari) approved with an FSGS indication pathway; targeted trials (e.g., APOL1 inhibitors).
Polycystic Kidney Disease (ADPKD)
~140K diagnosed US. Genetics and family testing, how fast PKD may progress (Mayo imaging class), blood-pressure control, the kidney-protecting medicine tolvaptan, managing cyst pain/infection, liver cysts, brain-aneurysm screening, and planning for transplant.
Primary Hyperoxaluria
~1-3 per million. RNAi therapies lumasiran (Oxlumo) and nedosiran (Rivfloza) — disease-altering for kidney-stone/failure risk.
Eye 1 available, 4 coming
Geographic Atrophy (Advanced Dry AMD)
The first FDA-approved treatments — Syfovre and Izervay — with honest expectations and long-term data, the retinal-vasculitis safety warning, OCT/FAF monitoring, AREDS2, the gene- and cell-therapy pipeline, and low-vision support.
Diabetic Retinopathy / Macular Edema
~10M US with some retinopathy. Faricimab and longer-acting anti-VEGF; expanding role of earlier intervention in non-proliferative disease.
Glaucoma
~4.2M US. Eye-pressure and optic-nerve testing, pressure-lowering drops (all classes), SLT and Direct SLT laser (now first-line), minimally invasive (MIGS) and traditional surgery, sustained-release implants (iDose TR travoprost, Durysta), and angle-closure emergencies.
Inherited Retinal Diseases (RP / LCA)
~200K US across IRDs. Voretigene (Luxturna) for RPE65 disease; broad gene-therapy and optogenetic pipeline.
Wet (Neovascular) AMD
~1.5M+ US. Faricimab (dual Ang-2/VEGF) and high-dose aflibercept extend treatment intervals; port delivery system.
Women's Health 0 available, 4 coming
Endometriosis
~1 in 10 women. How it's diagnosed (often without surgery), pain relief and hormonal treatments, GnRH-antagonist medicines (elagolix, relugolix combination), surgery, fertility and IVF, adenomyosis, and managing chronic pelvic pain.
Polycystic Ovary Syndrome
~5M+ US. GLP-1 receptor agonists increasingly used for metabolic and reproductive features; phenotype-based management.
Preeclampsia
~1 in 25 US pregnancies. sFlt-1/PlGF ratio biomarker test (FDA-cleared 2023) for short-term risk prediction; aspirin prophylaxis.
Uterine Fibroids
~26M US (symptomatic in many). Oral GnRH antagonist combinations (relugolix-Myfembree, elagolix-Oriahnn); uterine-sparing options.
Mental Health 3 available, 4 coming
Depression & Anxiety
Evidence-based psychotherapy, medication options, treatment-resistant approaches, lifestyle interventions, crisis resources, and when to seek specialist care.
Available NowSchizophrenia
Antipsychotic selection, clozapine pathway, LAI formulations, cognitive remediation, supported employment, family psychoeducation, and crisis planning.
Anorexia Nervosa
~1M+ US (lifetime). Higher-calorie refeeding evidence; olanzapine adjunct data; psilocybin and other novel-treatment trials.
Bipolar Disorder
A lifelong mood disorder of mania/hypomania and depression. The types (bipolar I, II, cyclothymia), diagnosis, mood stabilizers (lithium, valproate, lamotrigine) and antipsychotics for mania and bipolar depression, staying well and preventing relapse, suicide-safety planning, talk therapy, and pregnancy.
Obsessive-Compulsive Disorder
~2.5M US. Refined exposure-based therapy access; deep brain stimulation and TMS for refractory disease.
Opioid Use Disorder
~6M US. Expanded buprenorphine access; high-dose and extended-release formulations; contingency management.
Post-Traumatic Stress Disorder
~13M US in a given year. Trauma-focused therapy evidence; MDMA-assisted therapy under regulatory review; stellate-ganglion-block research.
Sleep & ENT 2 available, 2 coming
Sleep Disorders
Insomnia and CBT-I, restless legs syndrome, obstructive sleep apnea, circadian rhythm disorders, sleep studies, medications and devices, and practical implementation.
Meniere's Disease
~600K US. Refined diagnostic criteria; intratympanic therapy; endolymphatic-hydrops imaging research.
Obstructive Sleep Apnea
~30M US (most undiagnosed). Tirzepatide (SURMOUNT-OSA, FDA Dec 2024) — first drug ever approved for OSA; hypoglossal nerve stimulation expanding.
Sudden Sensorineural Hearing Loss
~66K new/yr US. Time-sensitive corticosteroid therapy (oral and intratympanic); the 'ear emergency' message.
Infectious Disease 1 available, 1 coming
HIV
~1.2M US. Long-acting injectable cabotegravir/rilpivirine; lenacapavir (twice-yearly); lenacapavir PrEP (PURPOSE trials, FDA 2025).
Tuberculosis
~8-9K new/yr US; massive globally. Shorter all-oral regimens (BPaL/BPaLM) for drug-resistant TB; rapid molecular diagnostics.
Endocrine 16 available, 0 coming
Graves' Disease
The most common cause of an overactive thyroid. Diagnosis and antibody (TRAb) tests, antithyroid medicines, radioactive iodine and thyroid surgery, beta-blockers, thyroid eye disease, thyroid-storm warning signs, pregnancy, and life after treatment.
Available NowThyroid Eye Disease
~15-20K new/yr US. Teprotumumab (Tepezza) — first drug to reduce proptosis without surgery; new IGF-1R agents in development.
HCM
A comprehensive guide for hypertrophic cardiomyopathy (HCM): diagnosis, mavacamten (Camzyos), aficamten (Myqorzo), SCD risk and ICD decisions, septal myectomy, exercise guidance, genetic testing, clinical trials, and resources for patients and families.
Available NowIBD
A comprehensive guide to Crohn's disease and ulcerative colitis: diagnosis, biologic and small-molecule therapy (IL-23 inhibitors, JAK inhibitors, S1P modulators, anti-TNF, vedolizumab), treat-to-target monitoring, surgery, diet, pregnancy, ASUC management, perianal disease, and practical resources for patients, caregivers, and clinicians.
Available NowBeta-Thalassemia
A practical, evidence-based guide to beta-thalassemia for patients and caregivers. Covers diagnosis, transfusions, iron chelation, luspatercept, mitapivat, stem cell transplant, and gene therapy (Casgevy and Zynteglo). Updated May 2026.
Available NowSMA
Practical guide for patients and families on spinal muscular atrophy (SMA): newborn screening, genetic diagnosis, the three FDA-approved SMN-targeted therapies (Zolgensma, Spinraza, Evrysdi), multidisciplinary care, daily life, and resources including Utah-specific services.
Available NowDMD
A practical, evidence-based guide for families and caregivers navigating Duchenne muscular dystrophy: diagnosis and genetic testing, corticosteroid therapy (deflazacort, prednisone, vamorolone with 8-year data), exon-skipping and gene-targeted treatments, the November 2025 Elevidys safety update, givinostat, cardiac and respiratory care, scoliosis and bone health, equipment and school planning, transition to adult life, and the 2025–2026 treatment landscape including next-generation therapies (del-zota, z-rostudirsen, deramiocel, RGX-202, CRISPR gene editing).
Available NowLupus (SLE)
A practical, evidence-based guide for patients and families navigating systemic lupus erythematosus (SLE): diagnosis and blood tests (ANA, anti-dsDNA, complement), hydroxychloroquine as foundation therapy, steroid minimization, biologic therapies (anifrolumab/Saphnelo, belimumab/Benlysta), lupus nephritis treatment (voclosporin/Lupkynis, obinutuzumab/Gazyva approved October 2025), antiphospholipid syndrome, pregnancy planning, health disparities, CAR-T cell therapy for refractory disease, deucravacitinib and emerging therapies, flare management, and living well with lupus.
Available NowEndometrial Cancer
A comprehensive, evidence-based guide for endometrial cancer: molecular classification (POLE, MSI-H, p53-abnormal, NSMP), surgery and staging with sentinel lymph node mapping, adjuvant therapy decisions, immunotherapy combinations (dostarlimab, pembrolizumab), targeted therapies (lenvatinib, trastuzumab deruxtecan), fertility preservation, survivorship, and practical resources for patients and families.
Available NowType 1 Diabetes
A comprehensive, evidence-based guide for type 1 diabetes: autoantibody screening and staging, insulin therapy optimization, CGM and automated insulin delivery systems, teplizumab immunotherapy, complication prevention, stem cell therapies, pregnancy management, psychosocial care, and practical resources for patients and families.
Available NowBalance & Dizziness Disorders
A comprehensive guide for balance and dizziness disorders: BPPV, Meniere's disease, vestibular migraine, vestibular neuritis, PPPD, vestibular rehabilitation, falls prevention, and practical resources for patients and families.
Available NowAL Amyloidosis
A comprehensive guide for AL amyloidosis (light chain amyloidosis): diagnosis, amyloid typing, treatment options including daratumumab, stem cell transplant, clinical trials, supportive care, and resources for patients and families.
Available NowTGA, TEA, TIA & Related Conditions
A comprehensive guide to transient global amnesia (TGA), transient epileptic amnesia (TEA), transient ischemic attack (TIA), and related conditions — for patients, families, and healthcare professionals.
Available NowAutism Spectrum Disorder
A comprehensive guide to autism spectrum disorder (ASD): diagnosis, evidence-based therapies, medications for co-occurring conditions, educational rights, transition to adulthood, and support resources for individuals and families.
Available NowPCOS & Early Menopause
A comprehensive guide to PCOS and early menopause (POI): diagnosis, treatment, fertility options, metabolic health, hormone replacement, and support resources for women and families.
Available NowADHD & OCD
A comprehensive guide to ADHD and OCD: diagnosis, medications, therapy (CBT/ERP), managing co-occurring conditions, school and workplace accommodations, daily strategies, and support resources for patients and families.
Available NowAsthma
A comprehensive guide to asthma: diagnosis, inhaler therapy, ICS-formoterol reliever strategy, asthma action plans, trigger management, severe asthma biologics, and practical daily management for patients and families of all ages.
Clinical Algorithms
Evidence-based clinical decision support for healthcare practitioners — structured data tables, treatment algorithms, regimen dosing, guideline concordance, and adverse event management.
Not a clinician? You’re welcome to forward any of these to your own doctor or care team — just share the link. They’ll still need to verify their credentials (NPI number or professional license) to open it.
Cancer 0 available, 19 coming
Colon Cancer
TNM staging, molecular profiling, adjuvant regimen dosing (IDEA framework), biomarker-directed metastatic therapy, AE management, and NCCN surveillance.
View → Available Now Clinical AlgorithmsGlioblastoma
WHO 2021 classification, MGMT-guided therapy, Stupp protocol, TTFields (EF-14), elderly adaptations, RANO response criteria, and dexamethasone management.
View → Available Now Clinical AlgorithmsLung Cancer (NSCLC)
Biomarker-directed treatment algorithms, perioperative strategies, immunotherapy, targeted therapy sequencing, resistance management, and decision support.
View → Available Now Clinical AlgorithmsMultiple Myeloma
IMWG diagnostic criteria, R-ISS risk stratification, quadruplet frontline therapy, ASCT, bispecific antibodies, CAR-T, MRD-guided approaches, and treatment algorithms.
View → Available Now Clinical AlgorithmsNon-Hodgkin Lymphoma
WHO 2022 classification, Lugano staging, R-CHOP/Pola-R-CHP for DLBCL, follicular lymphoma, mantle cell protocols, CAR-T and bispecific antibodies, prognostic indices.
View → Available Now Clinical AlgorithmsPancreatic Cancer
Resectability & molecular profiling, neoadjuvant strategy, surgical/volume principles, PRODIGE-24 adjuvant & first-line selection (incl. NALIRIFOX/NAPOLI-3), the KRAS frontier (daraxonrasib/RASolute 302), PARP maintenance, PERT/biliary/VTE/pain management, and evidence-graded tables.
View → Available Now Clinical AlgorithmsProstate Cancer
NCCN risk stratification, ISUP grading, active surveillance protocols, radiation dose-escalation, mCSPC intensification trials, mCRPC sequencing, and PSMA-targeted therapy.
View → Available Now Clinical AlgorithmsBreast Cancer
Subtype-directed algorithms (HR+/HER2-, HER2+, HER2-low, TNBC), biomarker panel and IHC cutoffs, neoadjuvant/adjuvant protocols, metastatic sequencing, ADC and CDK4/6 toxicity management, dosing tables, and evidence grades.
View → Available Now Clinical AlgorithmsThyroid Cancer
ATA 2015/2023 guidelines, NCCN v2.2026, molecular-guided FNA, Bethesda-to-surgery algorithms, RAI dosimetry, dynamic risk stratification, RET/BRAF/NTRK-directed therapy, and MTC monitoring.
View → Available NowAcute Lymphoblastic Leukemia
~6K new/yr US. Blinatumomab moving into frontline consolidation (E1910); CAR-T (brexucabtagene, tisagenlecleucel); MRD-guided therapy.
Available NowAcute Myeloid Leukemia
~20K new/yr; ~11K deaths. Menin inhibitor revumenib (Revuforj, FDA 2024) for KMT2A/NPM1; expanding IDH1/2 and FLT3 inhibitors; oral azacitidine maintenance.
Adrenocortical Carcinoma
~1-2 per million/yr. Mitotane plus chemotherapy standard; immunotherapy and targeted trials; hormone-excess management.
Anal Cancer
~10K new/yr US. Immunotherapy in advanced disease; HPV-driven prevention and high-resolution-anoscopy screening (ANCHOR).
Bladder Cancer
~83K new/yr US. Enfortumab vedotin + pembrolizumab (EV-302) transformed first-line metastatic; nadofaragene and N-803 for BCG-unresponsive NMIBC.
Castleman Disease
~5-6K new/yr US (all types). Siltuximab for idiopathic multicentric disease; sirolimus and JAK-pathway trials; CDCN-driven research.
Cervical Cancer
~14K new/yr US. Pembrolizumab + chemoradiation (KEYNOTE-A18); tisotumab vedotin for recurrent disease; HPV-driven prevention.
Available NowCholangiocarcinoma (Bile Duct Cancer)
~8-12K new/yr US. FGFR2 inhibitors (pemigatinib, futibatinib), IDH1 inhibitor ivosidenib, durvalumab+chemo (TOPAZ-1) first-line.
Available NowChronic Lymphocytic Leukemia
~21K new/yr; ~200K prevalence. Fixed-duration BTK+BCL2 (venetoclax-based) combinations; pirtobrutinib for BTK-resistant disease.
Cutaneous T-Cell Lymphoma (Mycosis Fungoides)
~3K new/yr US. Mogamulizumab; expanding skin-directed and systemic options; stage-driven therapy.
Desmoid Tumors
~5-6 per million/yr. Nirogacestat (Ogsiveo, 2023) — first FDA-approved therapy; gamma-secretase inhibition.
Diffuse Large B-Cell Lymphoma
~25K new/yr US. Bispecifics epcoritamab and glofitamab; pola-R-CHP first-line (POLARIX); CAR-T moved to second line.
Diffuse Midline Glioma / DIPG (Pediatric)
~300-400 new/yr US. Dordaviprone (Modeyso) accelerated approval (2025) for H3 K27M-mutant disease — first targeted option.
Endometrial Cancer
~67K new/yr. Dostarlimab+chemo (RUBY) and pembrolizumab+chemo (KEYNOTE-868/NRG-GY018) reshaped first-line advanced/recurrent disease; molecular classification.
Esophageal Cancer
Staging discipline, mandatory biomarkers (PD-L1/HER2/MMR/CLDN18.2), ESOPEC (FLOT>CROSS for adeno), CheckMate-577 adjuvant nivolumab, first-line IO sequencing, HER2/T-DXd, irAE management, and evidence-graded tables throughout.
Ewing Sarcoma
~200 new/yr US. Refined multimodal therapy; trials of targeted agents; survivorship-focused care.
Gastric Cancer
~27K new/yr US. Zolbetuximab (Vyloy) for Claudin 18.2-positive tumors; trastuzumab deruxtecan; IO by PD-L1 status.
Clinical AlgorithmsHead and Neck Cancer
Subsite & HPV/EBV-stratified staging, cisplatin chemoradiation, perioperative pembrolizumab (KEYNOTE-689), CPS-guided R/M immunotherapy, nasopharyngeal carcinoma, organ preservation & toxicity — evidence tables.
View → Available NowHepatocellular Carcinoma (Liver Cancer)
~42K new/yr US. Atezolizumab+bevacizumab and durvalumab+tremelimumab first-line; IMbrave050 adjuvant data; expanding earlier-stage IO.
Low-Grade / IDH-Mutant Glioma
~5-6K new/yr US. Vorasidenib (Voranigo, FDA 2024) — first targeted therapy for grade 2 IDH-mutant glioma (INDIGO trial).
Melanoma
~100K new/yr US. Tumor-infiltrating lymphocyte therapy lifileucel (Amtagvi, 2024); adjuvant IO; mRNA-4157 personalized vaccine (with pembrolizumab) phase 3.
Merkel Cell Carcinoma
~3K new/yr US. Avelumab and pembrolizumab — checkpoint inhibitors transformed this aggressive skin cancer; neoadjuvant IO trials.
Mesothelioma
~3K new/yr US. Nivolumab+ipilimumab first-line (CheckMate-743); perioperative IO trials; ADCs in development.
Neuroblastoma
~700-800 new/yr US. Anti-GD2 immunotherapy (dinutuximab, naxitamab) standard in high-risk disease; eflornithine maintenance.
Osteosarcoma
~1K new/yr US. Limb-salvage surgery advances; immunotherapy and targeted trials; metastatic-disease research.
Ovarian Cancer
~20K new/yr; ~12K deaths. PARP-inhibitor maintenance (HRD-guided); mirvetuximab soravtansine for folate-receptor-alpha-positive disease.
Available NowRenal Cell Carcinoma (Kidney Cancer)
~82K new/yr US. IO-TKI combinations standard; belzutifan (HIF-2alpha inhibitor) for VHL and advanced disease; adjuvant pembrolizumab.
Retinoblastoma
~200-300 new/yr US. Intra-arterial and intravitreal chemotherapy enable eye preservation; genetic (RB1) testing and counseling.
Small Cell Lung Cancer
VALG/TNM staging, limited-stage chemoradiation + consolidation durvalumab, extensive-stage chemoimmunotherapy (IMpower133/CASPIAN/IMforte), DLL3-targeted tarlatamab with CRS/ICANS management, regimen dosing, CNS & paraneoplastic care, and the molecular-subtype pipeline.
View →Soft Tissue Sarcoma
~13K new/yr US. Subtype-specific advances; nirogacestat for desmoids; afamitresgene autoleucel (T-cell therapy) for synovial sarcoma (2024).
Thymoma & Thymic Carcinoma
~400-500 new/yr US. Refined multimodal therapy; immunotherapy use tempered by autoimmune risk; paraneoplastic awareness.
Uveal Melanoma
~2.5K new/yr US. Tebentafusp (Kimmtrak) — first therapy to extend overall survival in metastatic disease (HLA-A*02:01 patients).
Neurological 0 available, 30 coming
Alzheimer's Disease
NIA-AA revised diagnostic criteria, plasma p-tau217 biomarker integration, anti-amyloid antibody protocols, ARIA monitoring, APOE-stratified risk, and treatment algorithms.
View → Available Now Clinical AlgorithmsALS
Revised El Escorial and Gold Coast criteria, ALSFRS-R/King’s staging, genetic evaluation, pharmacotherapy, NIV indications, gastrostomy timing, symptomatic management, and palliative care.
View → Available Now Clinical AlgorithmsMSA & Alpha-Synucleinopathy
MDS 2022 MSA criteria, autonomic management, supplement evidence grading, and clinical decision support for alpha-synucleinopathies.
View → Available Now Clinical AlgorithmsMyasthenia Gravis
Antibody-driven classification, MGFA staging, FcRn inhibitor selection, complement inhibitor management, thymectomy, crisis protocols, and treatment algorithms.
View → Available Now Clinical AlgorithmsParkinson’s Disease
MDS diagnostic criteria, levodopa formulations, dopamine agonist dosing, COMT/MAO-B inhibitors, DBS patient selection, motor fluctuation algorithms, and non-motor management.
View →Angelman Syndrome
~1 in 12-20K. Antisense-oligonucleotide programs targeting UBE3A in trials; symptomatic-care optimization.
CADASIL
~1 in 25-50K. Genetic diagnosis (NOTCH3); supportive management; emerging therapeutic research.
Cerebral Cavernous Malformation
~1 in 200-600. Propranolol and other repurposed-drug trials; familial-form genetic testing; imaging-surveillance guidance.
Charcot-Marie-Tooth Disease
Demyelinating-vs-axonal classification and electrodiagnosis, genetic-testing pathway, the CMT-vs-CIDP/ATTR decision pathway, neurotoxic-drug stewardship (vincristine contraindicated), anesthesia, management with evidence grades, and the gene-directed pipeline.
View →Chronic Inflammatory Demyelinating Polyneuropathy
~20-30K US. Efgartigimod (Vyvgart) approved for CIDP (2024); maintenance immunoglobulin optimization.
Chronic Migraine
~4M US with chronic migraine. CGRP monoclonal antibodies and oral gepants for prevention and acute use; growing real-world evidence.
Cluster Headache
~1 in 1K. Galcanezumab for episodic cluster; non-invasive vagus nerve stimulation; oxygen and acute-treatment optimization.
Dravet Syndrome
~1 in 15-16K births. Fenfluramine and cannabidiol approved; STK-001 antisense oligonucleotide and gene-therapy trials.
Drug-Resistant Epilepsy
~1M US with refractory seizures. New antiseizure medications (cenobamate); responsive neurostimulation and laser ablation; surgical-evaluation push.
Dystonia
Two-axis classification, the treatable-mimic workup (levodopa trial, Wilson screen), botulinum toxin selection/dosing (incl. daxibotulinumtoxinA), oral agents, GPi-DBS (now full FDA PMA 2025), status dystonicus, acute dystonic reactions, combined/paroxysmal forms, and the non-motor/psychosocial burden.
View →Essential Tremor
~7M US. MRI-guided focused ultrasound thalamotomy — incisionless option; expanding bilateral treatment.
Fragile X Syndrome
~1 in 4-7K. Targeted trials (e.g., zatolmilast/BPN14770 PDE4D inhibitor) for cognition; refined behavioral care.
Friedreich Ataxia
~5K US. Omaveloxolone (Skyclarys, 2023) — first-ever approved treatment; gene therapy and frataxin-replacement programs advancing.
Available NowFrontotemporal Dementia
~50-60K US. Progranulin-raising therapies (latozinemab) and C9orf72-targeted ASOs in trials; AC Immune and others advancing.
Guillain-Barre Syndrome
~1-2 per 100K/yr. IVIG and plasma exchange standard; complement inhibitor (eculizumab) and other trials for severe disease.
Hereditary ATTR Amyloidosis with Polyneuropathy
~10-40K US (underdiagnosed). TTR silencers patisiran, vutrisiran, eplontersen; NTLA-2001 (Nextriva) one-time CRISPR therapy advancing.
Hereditary Spastic Paraplegia
~1-5 per 100K. Gene-discovery expansion; subtype-specific trials emerging; supportive-care optimization.
Huntington's Disease
~41K symptomatic US; ~200K at-risk. AMT-130 AAV gene therapy showed first-ever signal of slowed progression (2025); huntingtin-lowering ASO programs continuing.
Lambert-Eaton Myasthenic Syndrome
~3 per million. Amifampridine (Firdapse/Ruzurgi); strong association with small-cell lung cancer driving cancer screening.
Leber Hereditary Optic Neuropathy
~100 new/yr US. Idebenone; lenadogene nolparvovec gene-therapy trials; mitochondrial-targeted approaches.
Lennox-Gastaut Syndrome
~30-50K US. Cannabidiol and fenfluramine approved; cenobamate and other agents studied; dietary and device options.
Lewy Body Dementia
~1.4M US. Refined biomarkers (skin/CSF alpha-synuclein seed amplification); neuroleptic-sensitivity awareness; symptomatic-care advances.
Available NowVascular Dementia
VasCog-2-WSO (2025) criteria and subtypes, imaging workup, vascular risk-factor control and stroke prevention (SPRINT-MIND; AF anticoagulation vs microbleed/CAA risk), symptomatic cognitive/mood pharmacotherapy, mixed and monogenic (CADASIL) disease, and referral — for clinicians.
Available NowMixed Dementia
The most common substrate of dementia in older adults (Alzheimer’s + cerebrovascular). Treat both processes; anti-amyloid eligibility tempered by vascular/microbleed burden.
Available NowNormal Pressure Hydrocephalus
Diagnostic criteria and imaging (Evans index, DESH, callosal angle), tap test and extended lumbar drainage, shunt selection/technique and valve titration, the placebo-controlled PENS RCT (gait benefit; cognition/bladder less reliable), comorbid neurodegeneration, complications, and referral — for clinicians.
Available NowParkinson's Disease Dementia
MDS criteria and the 1-year rule (PDD vs DLB), cognitive profile, cholinesterase-inhibitor and neuropsychiatric algorithms, the neuroleptic-sensitivity protocol, deprescribing, delirium workup, hospital safety, and the investigational pipeline (blarcamesine, neflamapimod; ambroxol negative).
Available NowWernicke-Korsakoff Syndrome
Pathophysiology, Caine-criteria clinical diagnosis, empiric parenteral high-dose thiamine before glucose (treat on suspicion), dosing evidence (Dingwall RCT), the under-recognition problem, non-alcoholic WE, Korsakoff prognosis/rehabilitation, and prevention protocols (2025 ASMBS) — for clinicians.
Available NowHIV-Associated Dementia (HAND)
Frascati ANI/MND/HAD with the 2023 consensus refinement, neuropsychological workup, rigorous confounder exclusion, CSF viral escape, the CPE debate, aging/vascular comorbidity, adherence and long-acting ART, and supportive care — for clinicians.
Available NowCreutzfeldt-Jakob Disease (Prion)
Rapidly progressive prion dementia with myoclonus and ataxia; RT-QuIC + DWI-MRI diagnosis. No disease-modifying treatment — supportive/palliative; median survival months.
MOG Antibody Disease
~1-2 per 100K. Newly defined entity (MOGAD); rozanolixizumab and other trials; distinguished from MS and NMOSD.
Moyamoya Disease
~1 in 100K US (higher in East Asia). Revascularization surgery (bypass) is mainstay; refined patient selection and imaging.
Myotonic Dystrophy
DM1/DM2 genetics & spliceopathy, cardiac conduction surveillance & device decisions (sudden-death prevention), the anesthetic-risk protocol, mexiletine for myotonia, congenital DM1, pregnancy, multisystem management with evidence grades, and the RNA-targeted pipeline (del-desiran).
View →Narcolepsy
~150-200K US. Orexin-receptor agonists (oveporexton/TAK-861) in phase 3 — potentially disease-targeted, not just symptomatic.
Neuroendocrine Tumors (NETs)
~12K new/yr US; rising prevalence. Lutetium-177 dotatate (Lutathera) expanding to earlier lines; somatostatin-analog and targeted-agent advances.
Neurofibromatosis Type 1
2021 diagnostic criteria (vs Legius/mosaic), age-stratified surveillance, the MPNST/ANNUBP malignant-transformation algorithm, optic pathway glioma, MEK-inhibitor therapy & monitoring, the cognitive phenotype, treatable vascular/endocrine workup, breast-cancer surveillance, transition of care, and the pipeline.
View → Available NowNeuromyelitis Optica Spectrum Disorder
~15K US. Four approved biologics: eculizumab, satralizumab, inebilizumab, and ravulizumab (2024) — relapse prevention transformed.
Restless Legs Syndrome
~7-10M US with significant symptoms. Shift away from dopamine agonists (augmentation risk) toward alpha-2-delta ligands and iron repletion.
Rett Syndrome
~6-9K US. Trofinetide (Daybue, 2023) — first-ever approved drug; gene-therapy programs (e.g., TSHA-102) in trials.
Spinal Muscular Atrophy
~10-25K US. Onasemnogene (Zolgensma) gene therapy, nusinersen (Spinraza), risdiplam (Evrysdi); newer higher-dose and combination strategies.
Spinocerebellar Ataxias
~1-5 per 100K. Troriluzole and gene-specific antisense programs in trials; expanded genetic testing.
Trigeminal Neuralgia
~150K US. Microvascular decompression and modern radiosurgery/ablation; newer sodium-channel-blocker research.
Tuberous Sclerosis Complex
~50K US. mTOR inhibitors (everolimus) for SEGAs/angiomyolipomas; cannabidiol for seizures; surveillance protocols.
Autoimmune 0 available, 15 coming
Multiple Sclerosis
2024 McDonald criteria, DMT algorithms, progressive MS treatment including BTK inhibitors, safety monitoring, and decision frameworks for healthcare practitioners.
View → Available NowANCA-Associated Vasculitis (GPA/MPA)
~40-50K US. Avacopan (Tavneos) — oral C5a-receptor blocker enabling major steroid reduction; rituximab maintenance optimization.
Adult-Onset Still's Disease
~1-2 per million/yr. IL-1 (anakinra, canakinumab) and IL-6 inhibitors; recognition of macrophage-activation-syndrome risk.
Autoimmune Hepatitis
~100-200K US. Standard steroid/azathioprine plus emerging steroid-sparing strategies; refined diagnostic scoring.
Axial Spondyloarthritis
~1.5-3M US (incl. non-radiographic). IL-17 inhibitors and JAK inhibitors; non-radiographic axSpA recognition; earlier diagnosis push.
Behcet's Disease
~1 in 20K US (higher along Silk Road). Apremilast for oral ulcers; TNF and IL-1 inhibitors; organ-specific treatment frameworks.
Bullous Pemphigoid
~2-5 per 100K/yr (elderly). Dupilumab approved for bullous pemphigoid (2025) — first targeted biologic; steroid-sparing.
Dermatomyositis & Polymyositis
~10 per 100K. IVIG (Octagam 10%) approved for dermatomyositis; myositis-specific antibody-driven subtyping; JAK inhibitors.
Familial Mediterranean Fever
~1 in 200-1K in at-risk populations. Colchicine remains first-line; IL-1 inhibitors for colchicine-resistant disease; MEFV genetic testing.
Giant Cell Arteritis
~228K US over 50. Tocilizumab steroid-sparing; new IL-6 and GM-CSF-pathway trials; fast-track diagnostic pathways.
IgG4-Related Disease
~1-5 per 100K (likely underdiagnosed). Inebilizumab (MITIGATE trial, 2025) — first agent with a dedicated IgG4-RD program; rituximab widely used.
Inclusion Body Myositis
~5-10 per 100K over 50. No approved treatment; ulnar/finger-flexor pattern recognition; trials of myostatin and autophagy-targeted agents.
Pemphigus Vulgaris
~1-5 per million/yr. Rituximab first-line (with steroids) is now standard; FcRn and other targeted agents in trials.
Psoriatic Arthritis
~1.5M US. IL-17, IL-23, and JAK inhibitors; bimekizumab; domain-based treatment selection.
Rheumatoid Arthritis
ACR/EULAR classification & disease-activity assessment, treat-to-target, conventional/biologic/targeted synthetic DMARDs, JAK-inhibitor safety (ORAL Surveillance), extra-articular disease & pregnancy — evidence tables.
View → Clinical AlgorithmsSjogren's Syndrome
~0.4-3.1M US (wide estimates). Ianalumab, dazodalibep, and other B-cell/co-stimulation agents in phase 3 — first potential disease-modifying drugs.
View →Stiff Person Syndrome
~1-2 per million. No approved disease-specific drug; rituximab and immunotherapy used off-label; GAD/glycine-receptor antibody subtyping.
Systemic Lupus Erythematosus
~200K-300K US SLE. Anifrolumab uptake, deucravacitinib trials, and dramatic CD19 CAR-T results (Erlangen) producing drug-free remission.
Systemic Sclerosis (Scleroderma)
~100K US. Tocilizumab and nintedanib for SSc-ILD; autologous stem-cell transplant; CD19 CAR-T trials showing remission.
Heart & Vascular 0 available, 13 coming
Atrial Fibrillation
CHA2DS2-VASc-guided anticoagulation, PFA vs thermal ablation, early rhythm control, LAAO selection, antiarrhythmic protocols, and special population algorithms.
View → Available Now Clinical AlgorithmsATTR Cardiomyopathy
Non-invasive diagnostic algorithm, TTR stabilizer comparison, gene silencer protocols, ATTR-specific HF management, and ACC-aligned decision pathways.
View → Available Now Clinical AlgorithmsHeart Failure
GDMT four-pillar optimization, HFpEF therapeutics, ATTR-CM diagnosis and treatment, device therapy algorithms, advanced HF management, and guideline-aligned protocols.
View → Available Now Clinical AlgorithmsPulmonary Arterial Hypertension
Hemodynamic diagnosis, ESC/ERS risk-stratified algorithms, combination therapy sequencing, sotatercept integration, transplant referral criteria, and monitoring protocols.
View → Available Now Clinical AlgorithmsStroke
IV alteplase/tenecteplase protocols, mechanical thrombectomy selection (DAWN/DEFUSE 3), ICH management, SAH grading, anticoagulant reversal, and secondary prevention.
View →Aortic Stenosis
~1.5M+ US (moderate-severe). EARLY TAVR (2024) supports earlier intervention in asymptomatic severe disease; TAVR durability data maturing.
Arrhythmogenic Cardiomyopathy
~1 in 2-5K. Genetic-testing-driven diagnosis; exercise-restriction evidence; risk-stratified ICD decisions.
Brugada Syndrome
~1 in 2K (higher in Asia). Risk-stratification refinements; ajmaline-challenge use; ICD and ablation decision frameworks.
Cardiac Sarcoidosis
Underdiagnosed subset of sarcoidosis. Advanced imaging (cardiac MRI/FDG-PET) recognition; immunosuppression plus device therapy protocols.
Coronary Artery Disease (residual risk)
LDL-C targets & the full lipid-lowering toolkit (PCSK9 mAbs, inclisiran, bempedoic acid, lerodalcibep, investigational oral PCSK9 & Lp(a) agents), residual inflammatory & Lp(a) risk, antithrombotic strategy, SGLT2i/GLP-1 cardiometabolic therapy, revascularization, and a dosing/monitoring appendix — evidence-graded tables & guideline concordance.
View →Hereditary Hemorrhagic Telangiectasia
~1 in 5K (largely undiagnosed). Pomalidomide (PATH-HHT trial, 2024) reduced bleeding; anti-VEGF strategies; systemic therapy emerging.
Hypertrophic Cardiomyopathy
~700K US (most undiagnosed). Cardiac myosin inhibitors: mavacamten (Camzyos) and aficamten (SEQUOIA-HCM, FDA filing) — first disease-specific drug class.
Long QT Syndrome
~1 in 2K. Genotype-specific management; beta-blocker selection by subtype; left cardiac sympathetic denervation; gene-specific trials.
Marfan Syndrome
~1 in 5K. Losartan plus beta-blocker; refined aortic-surveillance and surgical-threshold guidance.
Mitral Regurgitation
~4M US. Transcatheter edge-to-edge repair expanding; new replacement devices; functional-vs-degenerative pathways.
Peripheral Artery Disease
~10-12M US. Low-dose rivaroxaban plus aspirin (VOYAGER PAD); revascularization and supervised-exercise advances.
Tricuspid Regurgitation
~1.6M US with significant TR. Transcatheter tricuspid repair (TriClip, FDA 2024) and replacement systems — first device options.
Venous Thromboembolism (DVT/PE)
~900K events/yr US. Catheter-directed and mechanical thrombectomy for selected PE/DVT; refined DOAC duration strategies.
Digestive & Liver 0 available, 11 coming
Liver Disease
MASLD/MASH nomenclature, non-invasive fibrosis staging (FIB-4/VCTE pathway), approved pharmacotherapy, cirrhosis management, HCC surveillance, and transplant referral criteria.
View → Available Now Clinical AlgorithmsPBC (Primary Biliary Cholangitis)
Diagnostic workup, UDCA response criteria, PPAR agonist therapy, pruritus management ladder, PBC-AIH overlap, transplant evaluation, and AASLD/EASL-aligned pathways.
View → Available Now Clinical AlgorithmsUlcers
H. pylori eradication, GI bleeding protocols, wound care algorithms, compression therapy, offloading, and pressure injury prevention.
View →Achalasia
~1 in 100K/yr. Per-oral endoscopic myotomy (POEM) widely adopted; high-resolution-manometry subtyping guides therapy.
Acute Hepatic Porphyria
~1 in 100K (symptomatic rarer). Givosiran (Givlaari) RNAi prophylaxis dramatically reduces attacks; refined diagnostic testing.
Celiac Disease
~2M US (most undiagnosed). First non-dietary therapies in trials (e.g., gluten-degrading enzymes, immune-tolerance approaches).
Chronic Pancreatitis
~90-150K US. Total pancreatectomy with islet autotransplantation for selected patients; endoscopic and pain-management advances.
Eosinophilic Esophagitis
~150K+ US, rising fast. Dupilumab (Dupixent) — first FDA-approved drug for EoE; budesonide oral suspension (Eohilia).
Gastrointestinal Stromal Tumor
~5-6K new/yr US. Ripretinib and avapritinib for specific mutations; mutation-guided sequencing of tyrosine kinase inhibitors.
Gastroparesis
~5M US with symptoms. Limited drug options; gastric per-oral endoscopic myotomy (G-POEM); newer prokinetic and device research.
Hepatitis B
Phase classification, AASLD/IDSA 2025 treatment indications, nucleos(t)ide/peginterferon selection, HCC surveillance, PMTCT, reactivation prophylaxis, hepatitis D (bulevirtide), and the functional-cure pipeline.
View → Available Now Clinical AlgorithmsHepatitis C
Universal screening & non-invasive fibrosis staging, pangenotypic DAA regimen selection, the AASLD/IDSA simplified & 2025 point-of-care test-and-treat algorithms, drug-interaction & regimen-selection tables, special populations (cirrhosis, HIV, CKD/dialysis, pregnancy, PWID, transplant), and post-SVR surveillance — evidence-graded.
View →Inflammatory Bowel Disease (Crohn's & UC)
~3.1M US. Risankizumab, mirikizumab, upadacitinib, etrasimod, guselkumab — multiple new mechanisms 2023-2025; treat-to-target with intestinal ultrasound.
Primary Sclerosing Cholangitis
~30-50K US. No approved disease-modifying drug yet; norUDCA, FXR/PPAR agents, and antibiotic-strategy trials active.
Short Bowel Syndrome
~10-20K US on parenteral support. Teduglutide (GLP-2 analog) reduces parenteral-nutrition dependence; next-generation GLP-2 agents (apraglutide).
Wilson Disease
~9-10K US. New chelation options and trientine formulations; bis-choline tetrathiomolybdate trials; gene therapy programs.
Blood & Immune 0 available, 9 coming
Sickle Cell Disease
Genotype-specific care, VOC protocols, disease-modifying therapy optimization, gene therapy and transplant patient selection, complication surveillance, and guidelines.
View →Aplastic Anemia
~2-3 per million/yr. Eltrombopag added to immunosuppression as frontline (improves response); transplant-vs-IST decisions refined.
Beta-Thalassemia
~1K+ transfusion-dependent US; far larger globally. Exa-cel (Casgevy) CRISPR cure; betibeglogene (Zynteglo) gene therapy; luspatercept and mitapivat reduce transfusion burden.
Diamond-Blackfan Anemia
~25-35 new/yr US. Steroids and transfusion standard; gene-therapy and novel-agent trials; ribosomal-genetics insight.
Fanconi Anemia
~1 in 130K births. Hematopoietic transplant refinements; gene therapy trials; intensive cancer-surveillance protocols.
Hemophagocytic Lymphohistiocytosis
~1 in 100K children; adult forms underdiagnosed. Emapalumab (anti-IFN-gamma) approved; refined HLH-2004 and trigger-directed treatment.
Hemophilia A & B
WFH/ISTH/NHF/ASH guidelines, severity-driven prophylaxis, PK-guided dosing, non-factor therapy positioning, gene therapy eligibility, inhibitor management, and perioperative protocols.
View → Available NowHereditary Angioedema
~1 in 50K US. Donidalorsen and garadacimab approved 2025; oral prophylaxis (berotralstat); NTLA-2002 one-time CRISPR therapy in trials.
Clinical AlgorithmsImmune Thrombocytopenia
Diagnosis of exclusion & bleeding-risk assessment, first-line corticosteroids & IVIG, second-line TPO-RAs, fostamatinib, rituximab & splenectomy, emerging BTK (rilzabrutinib)/FcRn (efgartigimod) agents, bleeding emergencies & pregnancy — evidence tables.
View →Inborn Errors of Immunity (SCID/CGD)
SCID ~1 in 58K births; many IEI types. Gene therapies for SCID and other IEIs; newborn SCID screening now universal in the US.
Myelodysplastic Syndromes
~15-20K new/yr US. Luspatercept first-line for lower-risk anemia (COMMANDS); imetelstat (Rytelo, 2024); molecular IPSS-M risk model.
Available NowMyelofibrosis
~13-20K US. Momelotinib (2023) for anemic patients; pacritinib; pelabresib and navitoclax combination trials.
Paroxysmal Nocturnal Hemoglobinuria
~1 in 100K US. Factor B/D inhibitors iptacopan (Fabhalta) and danicopan; pegcetacoplan — oral and proximal-complement options.
Polycythemia Vera
~100K US. Ropeginterferon alfa-2b (Besremi) — first interferon approved for PV; rusfertide (hepcidin mimetic) phase 3.
Thrombotic Thrombocytopenic Purpura
~3-4 per million/yr. Caplacizumab added to plasma exchange and immunosuppression; rituximab; recombinant ADAMTS13 for congenital TTP.
Metabolic & Genetic 0 available, 10 coming
Diabetes
ADA/EASD consensus algorithm, SGLT2i and GLP-1 RA outcome data, insulin titration protocols, complication screening, DKA/HHS management, and individualized A1C targets.
View →AL Amyloidosis
~4-5K new/yr US. Daratumumab-based regimens (ANDROMEDA) now standard; CAEL-101 and birtamimab fibril-directed trials.
Elevated Lipoprotein(a)
~64M US with high Lp(a). Pelacarsen, olpasiran, and lepodisiran — Lp(a)-lowering agents in phase 3; first potential targeted therapy.
Erythropoietic Protoporphyria
~1 in 75-200K. Afamelanotide (Scenesse) increases pain-free light exposure; dersimelagon (oral) trials.
Fabry Disease
~3-5K diagnosed US (underdiagnosed). Pegunigalsidase alfa (Elfabrio); oral chaperone migalastat; gene therapy and substrate-reduction trials.
Available Now Ultra-Rare — First Guide WorldwidePUS7 Deficiency (IDDABS)
~15 patients worldwide. Pseudouridine synthase 7 deficiency. Allelic variants, diagnostic workup, gene therapy feasibility, epitranscriptomic comparison.
Familial Hypercholesterolemia
~1 in 250 (~1.3M US, mostly undiagnosed). Inclisiran (twice-yearly siRNA), evinacumab for homozygous FH, lerodalcibep; cascade screening.
Gaucher Disease
~6K US. Established enzyme replacement and substrate reduction; gene therapy (PR001/LY3884961) trials; GBA1-Parkinson link research.
Lysosomal Acid Lipase Deficiency
~1 in 40-300K. Sebelipase alfa (Kanuma) enzyme replacement — disease-altering for Wolman disease and CESD.
Mitochondrial Diseases (MELAS/Leigh)
~1 in 5K combined. Supportive 'mito cocktails'; gene-specific and substrate trials; refined diagnostic genomics.
Niemann-Pick Disease Type C
~1 in 100-150K. Levacetylleucine (Aqneursa, 2024) and arimoclomol approved — first disease-targeted options.
Phenylketonuria
~16-20K US. Sepiapterin (Sephience, 2025) — new oral option; pegvaliase (Palynziq) for adults; gene-editing programs.
Available NowPompe Disease
~3-5K US. Avalglucosidase alfa (Nexviazyme) and cipaglucosidase alfa + miglustat (Pombiliti) — improved enzyme therapies.
Prader-Willi Syndrome
~1 in 15-30K. Diazoxide choline (DCCR) and other trials for hyperphagia; growth-hormone and behavioral management.
Type 1 Diabetes
~1.6-2M US. Teplizumab (Tzield) delays stage-3 onset; donislecel (Lantidra) allogeneic islet cells; VX-880/zimislecel stem-cell trials; automated insulin delivery...
Urea Cycle Disorders
~1 in 35K births. Nitrogen-scavenger therapies; liver transplant; mRNA and gene-therapy programs in development.
Musculoskeletal 0 available, 10 coming
Scoliosis
Cobb angle assessment, Lenke and SRS-Schwab classification, bracing protocols, scoliosis-specific exercise evidence, fusion, VBT, and SRS/SOSORT-aligned pathways.
View → Available NowAchondroplasia
~10K US. Vosoritide (Voxzogo) — first drug to address growth; oral infigratinib (FGFR inhibitor) trials.
Duchenne Muscular Dystrophy
~12-15K US. Delandistrogene moxeparvovec (Elevidys) gene therapy — label expanded 2024; exon-skipping agents; givinostat (first non-steroid for all genotypes).
Facioscapulohumeral Muscular Dystrophy
~16-40K US. Losmapimod (DUX4-pathway) phase 3 trials; improved genetic diagnostics.
Fibromyalgia
~4M US adults. Refined multimodal management; central-sensitization framework; emerging neuromodulation research.
Gout (refractory/tophaceous)
~9M US (subset refractory). Pegloticase co-administered with methotrexate (improves response/durability); treat-to-target urate lowering.
Limb-Girdle Muscular Dystrophy
~2 per 100K. Multiple gene-therapy programs by subtype; precise genetic subtyping increasingly essential.
Mucopolysaccharidoses (MPS I/II/III)
~1 in 25K combined births. Enzyme replacement; intrathecal and gene-therapy programs (e.g., for Sanfilippo) advancing.
Osteoarthritis
~33M US. No disease-modifying drug yet; trials of NGF inhibitors and structure-modifying agents; weight-loss/GLP-1 impact.
Osteoporosis
DXA/FRAX fracture-risk stratification, antiresorptive & anabolic pharmacotherapy, anabolic-first sequencing, drug holidays & the denosumab-discontinuation protocol, glucocorticoid-induced & male osteoporosis, secondary causes — evidence tables.
View →Polymyalgia Rheumatica
~700K US. Sarilumab approved for PMR (2023) — first biologic option; steroid-tapering strategies.
Vascular Ehlers-Danlos Syndrome
~1 in 50-200K. Celiprolol shown to reduce arterial events; genetic confirmation; emergency-planning protocols.
Respiratory 0 available, 5 coming
COPD
GOLD 2025/2026 algorithms, spirometric staging, eosinophil-guided ICS decisions, dupilumab and mepolizumab for type 2 inflammation, ensifentrine, and treatment pathways.
View → Available Now Clinical AlgorithmsCystic Fibrosis
Newborn screening algorithms, CFTR genotype-modulator eligibility, Alyftrek vs Trikafta sequencing, pulmonary management, transplant referral, and emerging therapies.
View → Available Now Clinical AlgorithmsIPF & Pulmonary Fibrosis
HRCT/MDD diagnosis, antifibrotic selection & sequencing (incl. nerandomilast/FIBRONEER, the first add-on for confirmed progression), PPF operationalized, AE-IPF management & goals of care, comorbidity & drug-interaction pharmacology, transplant timing, and guideline-aligned evidence tables.
View → Available NowAlpha-1 Antitrypsin Deficiency
~100K symptomatic; vastly underdiagnosed. Augmentation therapy plus emerging RNAi (fazirsiran) for liver disease; gene therapy programs.
Available NowBronchiectasis (non-CF)
~350-500K US. Brensocatib (DPP-1 inhibitor) — ASPEN trial positive, FDA approval 2025; first disease-modifying drug for bronchiectasis.
Chronic Rhinosinusitis with Nasal Polyps
~4M+ US. Biologics dupilumab, omalizumab, and mepolizumab — first drug class to shrink polyps and cut surgery.
Connective Tissue Disease-Associated ILD
Hundreds of thousands US (across CTDs). Nintedanib for progressive fibrosing ILD; nerandomilast (FIBRONEER-ILD) expanding antifibrotic options.
Long COVID
Millions US (estimates vary widely). No approved treatment; RECOVER trials and mechanistic studies (immune, autonomic, microclot, viral persistence) maturing.
Lymphangioleiomyomatosis
~3-5 per million women. Sirolimus stabilizes lung function; everolimus and newer mTOR-pathway trials; VEGF-D biomarker.
Sarcoidosis
Diagnosis & exclusion of mimics, Scadding staging, treatment indications, glucocorticoid/steroid-sparing/anti-TNF ladder (PREDMETH), cardiac/neuro/ocular disease, fibrotic disease & pulmonary hypertension, and an evidence-based read of the pipeline (EFZO-FIT, RESOLVE-Lung) — evidence tables.
View → Available NowSevere Asthma
~2.5M+ US with severe disease. Tezepelumab (anti-TSLP) covers eosinophil-low patients; expanding biologic landscape; biologic-driven remission as a goal.
Skin 0 available, 8 coming
Alopecia Areata
~700K US with active disease. Oral JAK inhibitors baricitinib, ritlecitinib, and deuruxolitinib (2024) — first systemic approvals.
Atopic Dermatitis (Eczema)
Diagnosis & severity assessment, barrier/topical therapy & phototherapy, type-2 biologics (dupilumab, tralokinumab, lebrikizumab, nemolizumab), oral JAK inhibitors & boxed-warning safety, conventional systemics, the atopic march, and lifespan management — evidence tables.
View →Chronic Spontaneous Urticaria
~1.5M US at any time. Omalizumab established; dupilumab approved (2025); remibrutinib (BTK inhibitor) trials.
Epidermolysis Bullosa
~25-30K US. Beremagene geperpavec (Vyjuvek) — first topical gene therapy (2023); birch-bark gel (Filsuvez); prademagene cell therapy.
Generalized Pustular Psoriasis
~1-7 per million. Spesolimab (Spevigo) — first approved IL-36-receptor antibody for flares and prevention.
Hidradenitis Suppurativa
~1% of US population. Secukinumab and bimekizumab approved; IL-17 and other biologics expanding beyond adalimumab.
Prurigo Nodularis
~150-200K US. Dupilumab and nemolizumab approved — first FDA-approved therapies for this intensely itchy disease.
Psoriasis (moderate-severe)
~7.5M US. Bimekizumab (dual IL-17A/F) and deucravacitinib (oral TYK2) — high skin-clearance options.
Vitiligo
~2-3M US. Ruxolitinib cream (Opzelura) — first FDA-approved repigmentation therapy; oral JAK inhibitors in trials.
Kidney 0 available, 3 coming
IgA Nephropathy
Targeted therapies (sparsentan, iptacopan, budesonide), proteinuria management, KDIGO-aligned treatment algorithms, and transplant considerations.
View → Available NowChronic Kidney Disease
~35M US. SGLT2 inhibitors and finerenone slow progression; FLOW trial — semaglutide reduces kidney events; GLP-1 era.
Focal Segmental Glomerulosclerosis
~5-7 per million/yr US. Sparsentan (Filspari) approved with an FSGS indication pathway; targeted trials (e.g., APOL1 inhibitors).
Polycystic Kidney Disease (ADPKD)
Genetics & diagnosis, total-kidney-volume/genotype progression risk (Mayo class, PROPKD), RAAS-based BP control, tolvaptan therapy & REMS monitoring, cyst-complication & polycystic-liver management, intracranial-aneurysm screening, and kidney replacement — aligned to KDIGO 2025, with evidence tables.
View →Primary Hyperoxaluria
~1-3 per million. RNAi therapies lumasiran (Oxlumo) and nedosiran (Rivfloza) — disease-altering for kidney-stone/failure risk.
Eye 0 available, 4 coming
Geographic Atrophy (Advanced Dry AMD)
C3 vs C5 inhibitor selection (Syfovre/Izervay), evidence tables and long-term extension data, cRORA/iRORA imaging, the Dec-2024 retinal-vasculitis warning and AE workup, the function-endpoint pipeline (vonaprument, gene/cell therapy), and decision frameworks.
View →Diabetic Retinopathy / Macular Edema
~10M US with some retinopathy. Faricimab and longer-acting anti-VEGF; expanding role of earlier intervention in non-proliferative disease.
Glaucoma
Diagnosis & staging, target-IOP setting, medical and laser therapy (SLT-first per LiGHT), MIGS and incisional surgery, angle-closure & secondary glaucomas, sustained-release delivery & progression monitoring.
View →Inherited Retinal Diseases (RP / LCA)
~200K US across IRDs. Voretigene (Luxturna) for RPE65 disease; broad gene-therapy and optogenetic pipeline.
Wet (Neovascular) AMD
~1.5M+ US. Faricimab (dual Ang-2/VEGF) and high-dose aflibercept extend treatment intervals; port delivery system.
Women's Health 0 available, 4 coming
Endometriosis
Diagnosis & empiric treatment (ESHRE 2022), hormonal suppression, GnRH antagonists/agonists with add-back & BMD monitoring, surgical excision, fertility & assisted reproduction, chronic pelvic pain & central sensitization, and adenomyosis — evidence tables.
View →Polycystic Ovary Syndrome
~5M+ US. GLP-1 receptor agonists increasingly used for metabolic and reproductive features; phenotype-based management.
Preeclampsia
~1 in 25 US pregnancies. sFlt-1/PlGF ratio biomarker test (FDA-cleared 2023) for short-term risk prediction; aspirin prophylaxis.
Uterine Fibroids
~26M US (symptomatic in many). Oral GnRH antagonist combinations (relugolix-Myfembree, elagolix-Oriahnn); uterine-sparing options.
Mental Health 1 available, 4 coming
Depression & Anxiety
Pharmacotherapy algorithms, switching and augmentation strategies, TRD management, neuromodulation protocols, psychotherapy matching, and suicide risk assessment.
View → Available Now Clinical AlgorithmsSchizophrenia
Antipsychotic pharmacotherapy including KarXT/Cobenfy, clozapine optimization, LAI protocols, metabolic management, and guideline-aligned algorithms.
View →Anorexia Nervosa
~1M+ US (lifetime). Higher-calorie refeeding evidence; olanzapine adjunct data; psilocybin and other novel-treatment trials.
Bipolar Disorder
Diagnosis & classification, acute mania & mixed states, bipolar depression, maintenance & relapse prevention, mood-stabilizer & antipsychotic safety and monitoring (lithium, valproate, lamotrigine, carbamazepine), suicide-risk management, and pregnancy & special populations — evidence-graded, CANMAT/ISBD- and NICE-concordant.
View →Obsessive-Compulsive Disorder
~2.5M US. Refined exposure-based therapy access; deep brain stimulation and TMS for refractory disease.
Opioid Use Disorder
~6M US. Expanded buprenorphine access; high-dose and extended-release formulations; contingency management.
Post-Traumatic Stress Disorder
~13M US in a given year. Trauma-focused therapy evidence; MDMA-assisted therapy under regulatory review; stellate-ganglion-block research.
Sleep & ENT 0 available, 2 coming
Sleep Disorders
ICSD-3 classification, OSA severity and CPAP evidence, hypoglossal nerve stimulation, CBT-I protocols, insomnia pharmacotherapy, narcolepsy management, and RLS algorithms.
View →Meniere's Disease
~600K US. Refined diagnostic criteria; intratympanic therapy; endolymphatic-hydrops imaging research.
Obstructive Sleep Apnea
~30M US (most undiagnosed). Tirzepatide (SURMOUNT-OSA, FDA Dec 2024) — first drug ever approved for OSA; hypoglossal nerve stimulation expanding.
Sudden Sensorineural Hearing Loss
~66K new/yr US. Time-sensitive corticosteroid therapy (oral and intratympanic); the 'ear emergency' message.
Infectious Disease 0 available, 1 coming
HIV
~1.2M US. Long-acting injectable cabotegravir/rilpivirine; lenacapavir (twice-yearly); lenacapavir PrEP (PURPOSE trials, FDA 2025).
Tuberculosis
~8-9K new/yr US; massive globally. Shorter all-oral regimens (BPaL/BPaLM) for drug-resistant TB; rapid molecular diagnostics.
Endocrine 0 available, 0 coming
Graves' Disease
Diagnosis & TRAb testing, antithyroid drug therapy & safety (agranulocytosis, PTU hepatotoxicity), radioactive iodine & thyroidectomy, beta-blockade, thyroid storm, Graves' orbitopathy, and pregnancy & special populations — evidence tables, ATA/ETA-concordant.
View → Available NowThyroid Eye Disease
~15-20K new/yr US. Teprotumumab (Tepezza) — first drug to reduce proptosis without surgery; new IGF-1R agents in development.
Clinical guides are designed for healthcare practitioners. Read our methodology.
Available NowHCM
Evidence-based clinical reference for HCM: diagnostic algorithm with phenocopy exclusion, cardiac myosin inhibitor comparison and prescribing, SCD risk stratification using 2024 AHA/ACC and ESC frameworks, septal reduction selection, AF anticoagulation, and monitoring protocols.
Clinical Reference → Available NowIBD
Evidence-based clinical decision support for IBD: diagnostic workup and Montreal classification, advanced therapy positioning (13-drug comparison with pivotal trial data), STRIDE-II treat-to-target protocols, ASUC Oxford pathway, perianal Crohn's algorithm, TDM targets, cancer surveillance, pregnancy safety, and guideline-aligned management for UC and CD.
Clinical Reference → Available NowBeta-Thalassemia
Clinical management of beta-thalassemia for healthcare professionals. TIF 2025-aligned protocols for transfusion, MRI-guided iron chelation, luspatercept and mitapivat, HSCT including haploidentical with PTCy, and gene therapies Casgevy (exa-cel) and Zynteglo (beti-cel). Includes evidence tables, Utah resources, and international perspective.
Clinical Reference → Available NowSMA
Clinical decision support reference for spinal muscular atrophy: SMN1/SMN2 genetic diagnosis, post-newborn-screening algorithms by SMN2 copy number, comparative selection and administration of onasemnogene abeparvovec, nusinersen, and risdiplam, multidisciplinary protocols, adult SMA, emerging therapies including apitegromab regulatory status as of May 2026, and international considerations. For healthcare professionals.
Clinical Reference → Available NowDMD
Evidence-based clinical reference on Duchenne muscular dystrophy for HCPs: dystrophin genotype analysis and therapy matching, comparative corticosteroid optimization (deflazacort, prednisone, vamorolone 8-year data), exon-skipping ASOs including next-generation AOCs and PPMOs, delandistrogene moxeparvovec (Elevidys) with the November 2025 FDA Boxed Warning and indication restriction, givinostat safety monitoring, deramiocel cell therapy (PDUFA Aug 2026), cardiac and respiratory surveillance protocols, orthopedic and rehabilitative management, adult transition, emerging therapies (del-zota, z-rostudirsen, RGX-202, PBGENE-DMD CRISPR), DMD added to RUSP December 2025, international regulatory landscape, and Utah-specific referral resources.
Clinical Reference → Available NowLupus (SLE)
Evidence-based clinical reference on systemic lupus erythematosus for HCPs: 2019 EULAR/ACR classification criteria, 2025 ACR treatment guideline, treat-to-target with DORIS remission and LLDAS, hydroxychloroquine optimization with AAO 2025 retinal screening revision, biologic therapy selection (anifrolumab 4-year TULIP LTE data, subcutaneous autoinjector 2026; belimumab including pediatric LN autoinjector June 2025), lupus nephritis protocols (voclosporin AURORA, obinutuzumab REGENCY Phase III — FDA-approved October 2025, EULAR 2025 LN update), steroid minimization, NPSLE attribution, APS management, pregnancy optimization, CAR-T cell therapy (145-patient review ACR 2025, RESET-SLE rese-cel, allogeneic anti-CD19), deucravacitinib POETYK SLE Phase 3, cardiovascular risk, health equity, and Utah-specific referral resources.
Clinical Reference → Available NowEndometrial Cancer
Evidence-based clinical reference for endometrial cancer: TCGA molecular classification integrated into FIGO 2023 staging, surgical management with SLN mapping (FIRES trial), risk-adapted adjuvant therapy (PORTEC-3 10-year data, PORTEC-4a molecular profile-based), first-line immunotherapy-chemotherapy (dostarlimab RUBY OS data, pembrolizumab NRG-GY018 Nature Medicine 2025), lenvatinib-pembrolizumab 5-year KEYNOTE-775, HER2-directed therapy (T-DXd DESTINY-PanTumor02/Endometrial01), selinexor TP53wt maintenance, fertility-sparing protocols (ESGO/ESHRE/ESGE 2023), RAINBO molecular-guided adjuvant program, Lynch syndrome universal MMR screening, NCCN v3.2025, and Utah referral resources.
Clinical Reference → Available NowType 1 Diabetes
Evidence-based clinical reference for type 1 diabetes: autoantibody staging (IAA, GAD65, IA-2, ZnT8), insulin formulation comparison, AID system selection (Omnipod 5, Control-IQ, 780G), teplizumab prescribing (Tzield, expanded to age 1+), glycemic targets by population, complication screening protocols, Vertex VX-880 stem cell therapy pipeline, ADA 2026 Standards of Care, ISPAD 2024, and Utah referral resources.
Clinical Reference → Available NowBalance & Dizziness Disorders
Evidence-based clinical reference for balance and dizziness disorders: HINTS exam, vestibular testing interpretation, BPPV repositioning techniques, Meniere's treatment ladder, vestibular migraine criteria, PPPD management, rehabilitation protocols, acoustic neuroma surveillance, and falls prevention.
Clinical Reference → Available NowAL Amyloidosis
Evidence-based clinical reference for AL amyloidosis: diagnostic algorithms, amyloid typing, organ staging, treatment selection, response monitoring, emerging therapies, and guideline-concordant protocols.
Clinical Reference → Available NowTGA, TEA, TIA & Related Conditions
Clinical reference for transient neurological events: TGA/TEA/TIA differential diagnosis, ABCD2 risk stratification, neuroimaging protocols, secondary prevention, and cognitive follow-up.
Clinical Reference → Available NowAutism Spectrum Disorder
Clinical reference for autism spectrum disorder: DSM-5-TR criteria, screening tools, behavioral interventions, pharmacotherapy for co-occurring conditions, genetic evaluation, and lifespan management protocols.
Clinical Reference → Available NowPCOS & Early Menopause
Clinical reference for PCOS and premature ovarian insufficiency: Rotterdam criteria, pharmacotherapy, fertility algorithms, HRT protocols, cardiometabolic monitoring, and guideline concordance for healthcare professionals.
Clinical Reference → Available NowADHD & OCD
Clinical reference for ADHD and OCD: DSM-5-TR criteria, stimulant and non-stimulant pharmacotherapy, SSRI dosing for OCD, CBT/ERP protocols, comorbidity management, treatment-resistant algorithms, and guideline concordance.
Clinical Reference → Available NowAsthma
Clinical reference for asthma: stepwise management aligned with GINA 2025/2026, phenotype-directed biologic selection, MART/SMART therapy, acute exacerbation protocols, inhaler device selection, and monitoring/step-down algorithms.
Clinical Reference →How Trouvera Works
We turn published medical research into actionable guides organized around your journey.
Find Your Stage
Select where you or your loved one are in the treatment journey — pre-surgery, active treatment, or recurrence.
Read What Matters Now
Get the questions to ask, the options to discuss, and the practical steps most relevant to your current situation.
Find Specialists Near You
Browse top medical centers by region with contact information, specialties, and clinical trial availability.
Life Doesn’t Stop at a Diagnosis
Behind every guide is a family trying to get back to ordinary moments — the park, the beach, the soccer game. That’s who we build this for.
Illustrative photography — not actual patients.
About Trouvera
Trouvera was created because too many patients and families face serious diagnoses without the information they need to prepare for medical conversations.
Our guides are produced using AI-assisted research synthesis with human editorial review. We use AI models to aggregate and organize published medical literature, clinical trial databases, and the protocols of major treatment centers, and every guide undergoes human editorial review before publication. Our guides are not written by treating physicians. We do not provide medical advice, and we do not replace your care team. Every important treatment decision must be made with your specialist physician, surgeon, and primary care doctor. Nothing on this site substitutes for those conversations. Read our full methodology for details on our production process.
Factual claims are drawn from peer-reviewed research and official clinical trial records. Evidence levels vary — some findings come from large randomized trials, while others are based on smaller or observational studies. Where possible, we note the strength of the underlying evidence so you can discuss it meaningfully with your doctors.
We believe that better-informed patients have better conversations with their doctors, ask better questions, and participate more fully in decisions about their care.
Trouvera is a project of Alpha Inception.